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ABSTRACT 
 
Colorectal cancer (CRC) is the third most common cancer, and the second most 
common cause of cancer mortality. Both somatic mutations and inherited genetic 
variation drive the development of CRC. Characterizing the underlying genetic 
changes is fundamental in basic cancer research. This knowledge may ultimately be 
translated into the development of more effective approaches for reducing cancer 
morbidity and mortality. The aim of this study was to gain novel insight into the 
molecular mechanisms behind CRC predisposition, as well as tumor progression 
and development.  
Microsatellite instability (MSI) arises due to a defective mismatch repair system and 
is a feature of Lynch syndrome and a subset of all CRCs. MSI tumors are prone to 
repeat mutations, which in coding regions usually lead to premature termination 
codons (PTC). PTCs that occur in the end of the coding region of a gene might 
escape nonsense-mediated decay mechanisms. In the first project, we characterized 
all genes that were overexpressed in MSI CRCs and predicted to escape decay when 
mutated. The mitotic checkpoint kinase TTK was identified as a putative oncogenic 
target gene, with decay-escaping mutations in 59% (105/179) of the MSI CRCs 
screened. TTK is known to have an essential role in spindle assembly checkpoint 
(SAC) signaling; however, the mutated protein did not show SAC weakening. While 
no evidence of oncogenic mechanisms was observed, the high mutation frequency of 
TTK argues for biological significance.  
 
Second, we sought to identify novel driver oncogenes with activating missense type 
changes in MSI CRCs. The exomes of 25 MSI tumors and respective healthy tissues 
were sequenced. A total of 15 candidate oncogenes with confirmed mutation hot 
spots were identified. Three genes, ZBTB2, PSRC1 and RANBP2, displayed hot spot 
mutations also in the validation set of 86 MSI CRCs. Interestingly, the protein 
interactomes of ZBTB2 and PSRC1 consisted of many known cancer-related proteins 
and proteins with molecular functions relevant to cancer development and 
progression. In addition, the CRC-associated mutant form of ZBTB2 was shown to 
increase cell proliferation. Additional work is needed to further clarify the role of the 
identified somatic mutations in CRC tumorigenesis. Our results support the 
previous notion that CRC genomes are heterogeneous, characterized by a few 
frequently mutated genes, such as BRAF and PIK3CA, and a much larger number of 
genes mutated at intermediate frequencies, such as HRAS and here-identified 
PSRC1, ZBTB2 and RANBP2. The candidate oncogenes identified in this thesis work 
might be used to develop personalized tumor profiling and therapy.  
 
Inherited susceptibility is estimated to be involved in approximately one-third of all 
CRCs. However, few of these cases are associated with well-known highly penetrant 
mutations leading to inherited cancer syndromes. The great majority of inherited 
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CRC susceptibility remains still molecularly unexplained. A recent systematic 
sequencing study on CRC reported a set of somatically mutated genes, termed 
candidate cancer (CAN) genes. In study III, we examined the mutational profiles of 
15 CAN genes for somatic mutations as well as for germline variants in 45 familial 
CRC cases. In our tumor set, six of the CAN genes were somatically mutated. In 
germline, three private missense variants were identified in CSMD3, EPHB6 and 
c10orf137. 
 
With novel sequencing tools at hand, another effort was performed with the aim to 
identify novel susceptibility genes for common familial CRC. In study IV, we 
sequenced the exomes of 96 independent cases with familial CRC. We focused our 
search on genes harboring rare putative loss-of-function (LoF) variants. In total, 11 
novel candidate CRC susceptibility genes emerged from our efforts with putative 
LoF variants. These variants were absent or extremely rare in the general population. 
Seven loss-of-heterozygosity events, involving four genes, were observed in the data. 
In each occasion, the losses targeted the wild-type allele (P=0.0078), providing 
further support that true culprits are among the eleven genes. This study provides 
an interesting set of candidate predisposing genes, which might explain a subset of 
common familial CRC.  
 
The germline variants identified in studies III and IV need to be validated in larger 
sample sets, representing different populations, to provide firm evidence for disease 
predisposition. Additional work is also needed to characterize the detailed 
functional and clinical relevance of the identified candidate CRC predisposing genes. 
This information, then, can ultimately be translated into tools for cancer prevention 
and early diagnosis of individuals carrying true predisposition alleles. 
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INTRODUCTION 
   
Cancer refers to a large group of diseases, which may originate from most of the cell 
types and organs of the human body. The most common cancers are carcinomas, 
which are of epithelial origin (http://www.cancer.fi/syoparekisteri/en/, Finnish 
Cancer Registry, 2011 Statistics). All cancer cells share one important characteristic: 
they grow and proliferate in defiance of normal control. They may also acquire the 
capability to invade, disseminate from the site of the primary tumor and colonize 
distant organs. Tumors can be either benign (localized, noninvasive), which is the 
most common type, or malignant (invasive, metastatic). Metastases spawned by 
malignant tumors are the cause of nearly all cancer related deaths (Mehlen & 
Puisieux, 2006).  
 
The development of cancer is a multistep process reflecting the accumulation of 
genetic and epigenetic alterations. These alterations drive the progression and 
transformation of cells from a normal to a more malignant state. The process in 
which tumors develop is analogous to that described in Darwinian natural selection. 
Alterations that increase the fitness of a neoplastic clone (cells with a common 
genotype) accumulate and result in clonal expansion. The fitness of a neoplastic cell 
is shaped by its interactions with other cells,  soluble factors and the extracellular 
matrix in its immediate microenvironment (Merlo et al., 2006; Hanahan & Weinberg, 
2000). Hanahan and Weinberg (2000) have described the following hallmark 
capabilities that a cell needs to acquire in order to reach a malignant state: sustained 
proliferative signaling, evasion of growth suppression, activation of invasion and 
metastasis, replicative immortality, induction of angiogenesis and resistance to cell 
death (Hanahan & Weinberg, 2000). Lately, two emerging hallmarks have been 
added to the list: reprogramming of energy metabolism and evading immune 
destruction. In addition, genomic instability and inflammation have been proposed 
as “enabling characteristics” that facilitate the acquisition of the above mentioned 
hallmarks (Hanahan & Weinberg, 2011). 
 
Cancer is generally a slowly progressing disease and the development of a clinically 
detectable solid tumor is estimated to take up to several decades (Loeb et al., 2003). 
The risk of developing cancer is influenced by environmental and lifestyle factors, as 
well as by the set of genomic variants present in the germline of an individual. Some 
of the most common lifestyle and environmental risk factors for cancer are smoking, 
diet and obesity. Moreover, infectious agents are estimated to cause approximately 
15 % of all cancers. Well-known examples are Helicobacter pylori in gastric cancer 
(Parsonnet et al., 1991) and human papillomaviruses in cervical cancer (Hausen & de 
Villiers, 1994).  
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REVIEW OF THE LITERATURE 
 
1 Cancer as a genetic disease 
 
It is now widely accepted that all cancers arise as a result of numerous alterations 
that have occurred in the DNA sequence of cancer cells. These sequence variants can 
be transmitted through the germline of an individual and result is cancer 
susceptibility or they can be somatically acquired mutations. The germline variants 
are present in the fertilized egg from which the individual develops and will thus be 
present in all the cells of the human body. Somatically acquired mutations, including 
base substitutions, insertions and deletions of bases, rearrangements and copy 
number alterations, occur in the genomes of cells upon mitotic cell division (Stratton 
et al., 2009). Additional mutations accumulate when cells divide further and only 
when several genes are defective, cancer will develop. It has been suggested that the 
great majority of cancers arise when two to eight sequential alterations have 
occurred, during several decades, in genes with functions relevant to cancer 
(Vogelstein et al., 2013) (Figure 1). 
 
 
 
          
 
 
Figure 1. Somatic mutations accumulate in a cell that will form a neoplastic tumor cell colony of a 
malignant cancer. A malignant cancer cell develops via a lineage of mitotic cell division from the 
fertilized egg. Somatic mutations (represented by colored symbols) accumulate over a lifetime and 
this process is affected by both intrinsic and environmental factors. A subset of these mutations are 
driver mutations, which confer selective growth advantage upon the neoplastic clone, while the great 
majority are neutral passenger mutations.  The figure was drawn based on Stratton et al., 2009. 
Somatic mutations occur in every cell division, at a rate of approximately 10 × 10−7, in 
a more or less random fashion (Araten et al., 2005). In a neoplastic clone that is to 
Chemotherapy 
Chemo-
therapy 
resistant 
recurrence 
Fertilized 
egg 
Infancy 
Adulthood 
Early clonal 
expansion 
Gestation 
Childhood 
Benign 
tumor 
Early 
invasive 
cancer 
Late 
invasive 
cancer 
Intrinsic 
mutation  
processes 
Environmental 
and lifestyle 
factors  Mutator  
phenotype 
Passenger mutations  
Driver mutations  
Nucleus 
  
11 
become a cancer, a subset of mutations has by chance occurred in genes essential for 
tumor development. Mutations in these genes, also called cancer genes confer 
selective growth advantage for the neoplastic clone, which then undergoes clonal 
expansion. Such driver mutations enable the cells to acquire hallmark capabilities, 
such as resistance to cell death or evasion of growth suppression. These capabilities 
are required for metastatic cancer to develop. There are also numerous passenger 
mutations in the final clonal expansion that do not confer selective growth 
advantage and are biologically neutral. These mutations were by chance present in 
the progenitor cell that later underwent clonal expansion (Greenman et al., 2007; 
Hanahan & Weinberg, 2000) (Figure 1). 
Other important factors that regulate tumorigenesis, in addition to DNA sequence 
alterations, are epigenetic alterations and microRNAs (miRNAs). The epigenome 
undergoes several alterations during tumor progression, such as genome-wide loss 
of DNA methylation (hypomethylation) and excessive promoter methylation at CpG 
islands (hypermethylation) (Shen & Laird, 2013). miRNAs are small non-coding 
RNAs of 20-22 nucleotides, which are typically differentially expressed in cancers 
and can alter the expression of cancer genes (Croce & Calin, 2005). 
 
1.1 General features of cancer genes 
 
Of all the cancer genes known to date, approximately 90% show somatic mutations, 
20% show germline mutations and 10% show both. The most common mutation 
types in these genes are chromosomal translocations, frequently seen in lymphomas, 
leukemias and sarcomas (Futreal et al., 2004). Cancer genes have classically been 
divided into oncogenes and tumor suppressor genes depending on their mutation 
patterns and the effect of the mutations on gene function and cellular processes. 
These classifications may be arbitrary and oversimplified, however, they facilitate 
certain molecular genetic analyses and the detection of specific mutation patterns 
(Vogelstein & Kinzler, 2004). 
 
1.1.1 Oncogenes 
 
Oncogenes are altered in cancers in ways that render the gene constitutively active or 
active under situations when the wild-type is not. On cellular level these alterations 
act in a dominant manner, meaning that one allele is usually sufficient to confer a 
selective growth advantage to the cell. The normal equivalents of oncogenes are 
called proto-oncogenes, and proteins encoded by these genes usually function as 
transcription factors, growth factors, signal transducers or apoptotic regulators. 
These proteins positively regulate cellular processes such as cell growth, survival 
and migration. When a proto-oncogene becomes activated by intragenic mutation, 
chromosomal translocation or gene amplification, it transforms into an oncogene 
and might contribute to the initiation and progression of cancer (Croce, 2008). Since 
  
12 
the identification of the first human oncogene HRAS, with a glycine to valine 
substitutions at codon 12 in the human bladder carcinoma cell line T24/EJ (Reddy et 
al., 1982), several human oncogenes have been discovered (Croce, 2008). 
 
Oncogenes are frequently activated by intragenic mutations. The patterns of 
mutations tend to be highly nonrandom, with most of the mutations enriched in 
certain regions of the protein. It has been estimated that typical oncogenes have > 
20% of missense mutations in recurrent positions (Vogelstein et al., 2013). The most 
commonly mutated oncogenes in human cancers are the RAS genes (KRAS, HRAS 
and NRAS), which code for small GTPases that are involved in transmitting signals 
within the cell. Oncogenic RAS mutations result in constitutive mitogenic signaling, 
one of the most fundamental trait of cancer cells (Pylayeva-Gupta et al., 2011). BRAF, 
acting downstream of RAS in the MAPK/ERK pathway, also shows activating 
mutations in many cancers, most commonly at codon V600. This residue is within 
the activating loop of the kinase domain and constitutively activates the enzyme. The 
activated kinase phosphorylates downstream targets, such as extracellular signal-
regulated kinase (ERK), which ultimately leads to aberrant cell growth (Wan et al., 
2004). Oncogenes can also be activated by chromosomal translocations, such as MYC 
in Burkitt’s lymphoma and BCR-ABL in Chronic Myelogenous Leukemia, or through 
gene amplification as often seen for MYC, EGFR and ERBB2 in several different 
cancers (Croce, 2008).  
 
1.1.2 Tumor-suppressor genes 
 
In normal cells, tumor-suppressor genes often function to restrain cell growth and 
division and to stimulate cell death. In cancer, these genes are frequently altered 
leading to loss of function or reduction in protein activity. Tumor-suppressor genes 
are recessive in nature: mutations in both alleles are generally required to confer a 
selective growth advantage to the cell. This principle is known as the “two-hit” 
hypothesis and was first proposed by Alfred Knudson (1971). According to this 
model, familial form of cancers may arise by two inactivating alterations of which 
one is inherited through the germline and the other is acquired somatically. 
Conversely, sporadic cancers require two somatically acquired hits and thus such 
cancers usually develop at a later age (Knudson, 1971). The inherited inactivated 
allele tends to show small intragenic mutations, whereas the remaining allele is 
usually inactivated by similar mutations or by loss of heterozygosity (LOH), caused 
by for instance mitotic recombination (Knudson, 2002). 
 
The RB1 gene is an example of a classical tumor suppressor gene (also known as a 
gatekeeper) that drives cell progression in a direct manner when both alleles are 
inactivated and predisposes to tumors of the retina (Friend et al., 1986; Kinzler & 
Vogelstein, 1997). RB1 is a critical regulator of cell-cycle progression and when 
inactivated leads to persistent cell proliferation and evasion of growth suppression 
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(Hanahan & Weinberg, 2011). The tumor suppressor TP53 is another key control 
node that regulates cell-cycle progression. The TP53 gene is mutated in half of all 
human cancers and the rest of the cancers often have alterations in its interaction 
partners. Unlike RB1, TP53 receives signals from within the cell upon several forms 
of cellular stress, such as hypoxia and DNA damage. Inactivated TP53 leads to 
resistance to programmed cell death (apoptosis) and evasion of growth suppression. 
Patients with Li-Fraumeni syndrome have germline mutations in TP53 (Vogelstein et 
al., 2000; Prives, 1998; Hanahan & Weinberg, 2011). Other well-known classical 
tumor suppressors are APC (Levy et al., 1994) in CRC, and BRCA1 (Miki et al., 1994) 
and BRCA2 in breast cancer (Wooster et al., 1995). 
 
There are exceptions to the classical two-hit hypothesis when a mutation or loss of a 
single-copy of a tumor suppressor gene plays a significant role in tumorigenesis. In 
some occasions, a single-copy event may be preferentially selected for in tumor 
evolution, instead of biallelic inactivation that might lead to cell death or senescence. 
The term haploinsufficiency refers to the scenario when inactivation of a single allele 
is enough for aberrant protein function and promotion of cancer (Santarosa & 
Ashworth, 2004). One example is the haploinsufficient loss of PTEN that can provide 
growth advantage, while avoiding senescent signals of TP53 that a complete loss of 
PTEN would induce. Another exception to the classical two-hit hypothesis is when a 
single-copy mutation functions in a dominant negative manner, interfering with the 
normal protein produced by the remaining wild-type allele (Berger et al., 2011). 
 
A subclass of tumor suppressor genes are the stability genes (also called caretakers). 
These genes promote tumorigenesis indirectly by creating genomic instability. 
Normally these genes function to keep the number of genetic alterations low but 
upon their inactivation the mutation rate in all other genes is increased. However, 
only mutations that target oncogenes or tumor suppressor genes will be 
preferentially selected for and have a tumor promoting effect. Similar to classical 
tumor suppressor genes, both alleles are generally inactivated in the tumor. Stability 
genes include the mismatch repair, nucleotide-excision repair and base-excision 
repair genes. Also genes involved in mitotic recombination and chromosomal 
segregation belong to this class, for example BRCA1 and ATM (Vogelstein & Kinzler, 
2004; Kinzler & Vogelstein, 1997).  
 
1.2 Inherited predisposition to cancer 
 
The great majority of common cancers arise sporadically and are highly influenced 
by environmental and lifestyle factors. An estimated 5-10% of all cancers are 
inherited, due to highly penetrant germline mutations that cause rare inherited 
cancer syndromes. Another 15-20% of all common cancers are known as “familial”, 
which can be defined as clustering of cancer in a family more frequently than 
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expected (Nagy et al., 2004). Still today, the molecular background of “familial” 
cancers remains largely unexplained. The familial clustering is most likely due to the 
inheritance of common low-penetrance alleles and rare moderate-penetrance alleles, 
as well as epistatic interactions (Fletcher & Houlston, 2010). Research has lately 
focused on identifying novel predisposing variants behind familial forms of cancer. 
However, challenges arise due to the multifactorial nature of the disease, related to 
the heterogeneity observed on both cellular and genetic level. Identification of novel 
susceptibility genes is important, not only to gain better understanding of cancer 
biology in general but also for the identification of novel targets for therapeutic 
interventions. Also, identifying individuals at increased risk is of immediate clinical 
relevance. 
 
1.2.1 Inherited cancer syndromes 
 
A small fraction of common cancers can be explained by high-penetrance germline 
mutations that cause hereditary cancer syndromes with often quite distinct clinical 
features. There are several characteristics of hereditary cancers, such as multiple 
affected individuals in the family over several generations, early age of onset, and 
multiple primary cancers in one individual. Many of the known cancer syndromes 
show complete penetrance by the age of 70. However, due to factors such as 
phenotypic variability and age-related penetrance, some families with an inherited 
cancer syndrome do not show the above mentioned characteristics (Nagy et al., 
2004). Predisposing alleles underlying rare hereditary cancer syndromes usually 
have a minor allele frequency (MAF) less than 0.1% and confer high-risk with odds 
ratio >10. However, on population level they confer a small attributable risk (Fletcher 
& Houlston, 2010).  
 
To date, more than 100 genes have been reported to cause Mendelian inherited 
cancer syndromes. Most syndromes fit autosomal dominant model with defects in 
tumor suppressor genes that conform to the two-hit model of cancer susceptibility.  
However, there are also syndromes that are of autosomal recessive nature, usually 
resulting from defects in stability genes (Cazier & Tomlinson, 2010). Classical genetic 
linkage-analysis and positional cloning has led to the discovery of many highly 
penetrant genes for common cancers. This was successfully performed for genes 
such as BRCA1 and BRCA2 (Hall et al., 1990; Wooster et al., 1995) in breast and 
ovarian cancer, APC (Bodmer et al., 1987; Nishisho et al., 1991)  and mismatch repair 
genes (Peltomäki et al., 1993; Lindblom et al., 1993) in CRC, and CDNK2A (Cannon-
Albright et al., 1992; Piepkorn, 2000) in melanoma.  
 
1.2.2 Other forms of cancer-predisposing variation  
 
Common cancers are known to cluster in families, and individuals with a first-
degree relative affected have a two-to-four-fold higher risk of developing cancer 
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(Goldgar et al., 1994; Johns & Houlston, 2001). Also, most common cancers show 
higher concordance in monozygotic twins than in dizygotic twins. Heritability has 
been estimated to account for 42, 35 and 27 % of the variation in susceptibility to 
prostate, colorectal, and breast cancer, respectively (Lichtenstein et al., 2000). Most 
known cancer predisposing genes cause Mendelian inherited cancer syndromes, and 
explain only a small part of the entire heritable fraction of common cancers. This has 
led researchers to question where the “missing heritability” can be found. Potential 
sources of “missing heritability” could be variants of low MAF (0.5% < MAF < 5%) or 
of rare variants (MAF < 0.5%). Another source might be structural variation, 
including copy number variants and copy neutral variation, such as translocations.  
(Manolio et al., 2009).  
 
The “rare variant hypothesis” proposes that a large fraction of the inherited 
susceptibility may be due to the summation of rare moderately penetrant risk alleles 
(with MAF ≤2 % and odds ratio ≥ 2) that each act independently and dominantly. 
These are thought to be mostly population specific due to founder effects that have 
resulted from genetic drift. Both next generation sequencing (NGS) and candidate 
gene sequencing approaches are thought to enable the identification of such variants 
(Bodmer & Bonilla, 2008; Bodmer & Tomlinson, 2010). To date, only few robustly 
validated moderate-penetrance genes have been identified in common cancers, such 
as CHEK2 (Meijers-Heijboer et al., 2002; Vahteristo et al., 2002) in breast cancer and 
MUTYH (Al-Tassan et al., 2002) in CRC.  
 
The “common disease-common variant” model proposes that alleles of high 
frequency (MAF >10 %) and low penetrance (typically odds ratio <1.5) contribute to 
the susceptibility of common cancers. Several common risk loci have successfully 
been identified for many common cancers by genome-wide association (GWA) 
studies. However, pinpointing the disease-causing variant at these risk loci has 
proven difficult (Fletcher & Houlston, 2010). The “rare variant hypothesis” and 
“common disease-common variant” models are contradictory, and a more 
continuous and comprehensive approach is more likely to model the true underlying 
genetic predisposition.  
 
It is also argued that much of the remaining inherited susceptibility can be explained 
by the co-inheritance of several genetic variants, known as the “polygenic model of 
predisposition”. Each individual is thought to carry a handful of variants of 
low/moderate-risk that exist in varying frequency in the population. An individual 
at very low risk might carry mainly low-risk alleles, whereas a person at higher risk 
might have one or more moderate-risk alleles (Fletcher & Houlston, 2010). It has 
been hypothesized that the polygenic basis of common diseases might be manifested 
in the regulation or function of one or more signaling pathways. Genetic variation at 
several different loci could cause many slight changes that together result in 
deregulation of key cellular signaling pathways (Sullivan et al., 2012).  
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2 The era of large-scale genome sequencing 
 
In 2008, the first human cancer genome was sequenced by using NGS, where 
thousands to millions of DNA templates are processed in parallel (Ley et al., 2008; 
Shendure & Ji, 2008). Today, the cost of NGS has reduced more than 100-fold since 
the first genomes were sequenced. In basic and clinical research, it is now routine to 
sequence several exomes (i.e., the coding regions of the genome) and whole genomes 
accurately and rapidly. Over the next few years several thousand more genomes will 
be sequenced. Also, it is estimated that, as the costs drop even further, routine NGS 
sequencing will become part of every clinic. This vast amount of data will provide us 
with a detailed picture of the underlying inherited variations and acquired somatic 
mutations that drive tumor development and progression. However, challenges 
emerge related to interpretation of NGS data in meaningful terms. Further progress 
in this area will require carefully designed studies that are optimized to detect causal 
variants. Ultimately, this data will provide considerable increase in the knowledge of 
cancer biology and potentially novel opportunities for the development of new 
cancer treatments (Vogelstein et al., 2013; Kilpivaara & Aaltonen, 2013).  
 
 2.1 Human genomic variation 
 
As a prerequisite for understanding how different germline variants contribute to 
cancer risk, we need to understand the spectrum of allelic variation in healthy 
individuals. This is particularly the case for population-specific rare variants that are 
thought to be enriched for disease susceptible variants (MacArthur et al., 2012). To 
date, several large-scale sequencing studies on human genomic variation have been 
performed, for example studies that are part of the 1000 Genomes Project. The 1000 
Genomes Project is an effort where 1,092 individuals from 14 populations (including 
93 individuals from Finland) have been low-coverage whole-genome and exome 
sequenced (1000 Genomes Project Consortium et al., 2012). The data provide 
researchers with a comprehensive resource on human genomic variation.  
 
It has been reported that every individual carries approximately 2,500 non-
synonymous variants at conserved sites and as many as 150 LoF variants (stop-gains, 
framesifting indels or splice-site variants). Most of the LoF variants are common 
(MAF >5%) or low-frequency (MAF 0.5-5%) with the number of rare LoF variants 
(MAF <0.5%) being much lower, approximately 10-20 per individual (1000 Genomes 
Project Consortium et al., 2012). Human genomic variation shows substantial 
population differences, especially for variations that are rare. More than half of all 
the rare variants found in the 1000 Genomes Project were found in a single 
population (Gravel et al., 2011; 1000 Genomes Project Consortium et al., 2012). These 
results highlight the challenge to replicate disease-association for rare variants in 
different populations and the challenge to find causal variants from the large 
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number of neutral background variation.  
 
2.2 Novel insights into cancer predisposition  
 
Until now, approaches for detecting rare/low frequency coding variants of moderate 
penetrance for common cancers have been poor. Attractive patient groups to search 
for such variants are common familial cases, with few affected first-degree relatives 
and early-diagnosed cancer patients. Common cancer families are usually too small 
for linkage analysis, and the variants are too rare to be detected in GWA studies. In 
addition, candidate gene screens have been heavily biased towards genes with 
previous supporting functional or genetic data (Bamshad et al., 2011). NGS, 
including exome and whole genome sequencing (WGS), is a powerful new tool to 
examine the underlying genetic architecture of common cancers in an unbiased and 
systematic manner (Figure 2).  
 
 
 
Figure 2. Genetic architecture of cancer risk. Genetic variants in the population can be placed on a 
continuum of allele frequency and effect size. Mendelian syndromes occupy the upper left circle, 
consisting of rare high-penetrance alleles mostly identified by linkage-analysis. GWA studies have 
proven successful in identifying common variants of low effect size (lower right). The middle, which 
consists of rare/low-frequnecy variants of varying effects have been fairly unexplored. Advances in 
sequencing technologies allow for the exploration of the relationship between such variants and 
cancer predisposition (figure drawn based on McCarthy et al., 2008). 
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Although NGS is considered a highly attractive approach, there are still challenges 
related to data interpretation. A key challenge is how to pinpoint key susceptibility 
alleles among a large number of non-pathogenic background variations and 
sequence artifacts. Also, optimal NGS study designs need to take into account 
variables, which include: inheritance pattern, population structure and the extent of 
locus heterogeneity. Such variables affect, for example, the sample size required to 
obtain sufficient power to detect robust disease-association. Often statistically weak 
associations need further support from additional information related to, for 
example, preferential selection of the locus in the tumor tissue or additional 
functional evidence (Bamshad et al., 2011; Bansal et al., 2010). 
 
To date, there are fairly few examples where NGS has been successfully utilized to 
identify novel cancer predisposing loci for common cancers. Several studies 
including small sample sets have reported novel predisposing cancer genes that 
have subsequently failed robust validation in other sample materials, for example 
PALB2 (Jones et al., 2009) and ATM (Roberts et al., 2012) in pancreatic cancer (Grant 
et al., 2013). WGS was successfully utilized in a study conducted in Iceland, where 
they identified a novel rare single-nucleotide variant at 8q24 that predisposes 
individuals to prostate cancer. The association of the rare variant was confirmed in 
other European populations, and it was shown to confer a slight increase in prostate 
cancer risk; however, the risk was higher (odds ratio = 2.90) compared to those 
variants identified previously by GWA studies (typically with odds ratios < 1.5) 
(Gudmundsson et al., 2012). In the near future, these studies will most likely be 
performed in a similar fashion to GWA studies, with very large sample sizes that 
allow for sufficient statistical evidence to pinpoint true predisposing variants based 
on the association evidence alone. In the meantime, it is important to optimize study 
design and data analysis strategies to detect pathogenic variants in smaller sample 
sets.  
 
2.3 Cancer genome landscapes 
 
Over the last years, comprehensive large-scale sequencing efforts have revealed new 
insights into the cancer genome landscapes of many common cancers. One of the 
largest ongoing efforts is that conducted by the Cancer Genome Atlas project, were 
20 “mutatomes” from different cancers are being profiled (Cancer Genome Atlas 
Network, 2012).  
 
The average number of somatically acquired alterations in a particular tumor largely 
depends on the tumor type, with most common solid tumors showing an average of 
33 to 66 non-synonymous somatic mutations. Outliers are melanoma and lung 
cancers, with a high number of mutations, and pediatric tumors and leukemias with 
a low number of mutations (Vogelstein et al., 2013) In addition, tumors with a DNA 
repair defect represent another group of outliers that have up to 1000 non-
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synonymous mutations per tumor (Palles et al., 2013; Cancer Genome Atlas 
Network, 2012). Recent efforts have also highlighted the fact that most somatic 
mutations in a given tumor type are passenger mutations and do not confer any 
selective growth advantage upon the cell. How to find the true driver genes in the 
full repertoire of somatic mutations is still a challenge; however, several prioritizing 
strategies have been proposed related to mutation frequency, gene length, gene 
mutation patterns and other parameters (Vogelstein et al., 2013).  
 
For most cancer types, there are a few genes that are mutated at high frequency and 
a much larger number of genes mutated infrequently. The genomic landscape of 
common cancers has thus revealed a similar topography of mountains and hills. 
Studies have shown that two tumors of the same histopathologic subtype are fairly 
distinct in respect to their genetic alterations (Sjöblom et al., 2006; Wood et al., 2007). 
Vogelstein et al. (2013) recently highlighted the need for better understanding of 
altered signaling pathways rather than individual genes. They proposed that all of 
the cancer genes can be classified into one or more of 12 pathways, and these 
pathways can be further organized into three core cellular processes: cell fate (for 
example APC and NOTCH), cell survival (for example RAS and PIK3CA) and 
genome maintenance (for example TP53 and MLH1) (Vogelstein et al., 2013). 
 
3 Colorectal cancer  
  
3.1 Introduction to colorectal cancer 
 
CRC is still one of the leading types of cancer. Worldwide, it’s the fourth most 
common cancer in men and the third in women. There is significant international 
variation in incidence rates; North America and Europe have high rates, and Asia, 
Africa and South America have low rates (Center et al., 2009). In Finland, the 
incidence is 27.9 per 100,000 in males and 19.4 per 100,000 in females; with 
approximately 2800 new cases diagnosed each year. According to the Finnish cancer 
registry data, the 5-year survival rate is around 60-65% for all cases 
(http://www.cancer.fi/syoparekisteri/en/). The lifetime risk of CRC in the general 
population is approximately 5-6 % (Jemal et al., 2008).  
 
CRC is a complex disease influenced by both genetic and environmental factors. The 
genetic risk factors will be described in detail in the next chapters. Lifestyle and 
environmental risk factors include, for instance, diet, physical inactivity and 
smoking (Giovannucci, 2002; Botteri et al., 2008). Interestingly, physical inactivity 
has been estimated to cause up to 10% of the burden of CRC (Lee et al., 2012).  
Environmental and lifestyle factors partly explain the high rate of CRC observed in 
the Western world. In addition, an increased risk for CRC has also been reported for 
individuals with inflammatory bowel disease (Dyson & Rutter, 2012). There are 
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factors that reduce CRC risk; one well established example is aspirin, which has been 
shown to reduce CRC risk and improve survival after diagnosis (Chia et al., 2012).  
 
There are two widely used staging systems when diagnosing CRC; the TNM (tumor, 
node, metastasize) staging system and the Dukes Classification (Compton & Greene, 
2004) (Table 1; modified from Union for International Cancer Control, 
http://www.uicc.org). Tumors of TNM stage I or II, which are local invasive cancers, 
can often be cured by surgical removal. Stage III tumors, which have spread to 
regional lymph nodes, are curable by surgery combined with adjuvant therapy in 
around 73 % of cases. Cancers that have metastasized (stage IV) are often fatal; 
however, improvements in anti-angiogenic therapy and EGFR based therapy have 
improved patient survival (Heinemann et al., 2013). Early detection of CRC has a 
crucial impact on survival. For patients with stage A disease, according to Dukes 
classification, the 5-year overall survival rate is as high as 95 %, but only 0-7 % for 
Dukes D stage patients (Weitz et al., 2005). Accurate cancer staging is important not 
only for appropriate evaluation of therapies, prediction of survival and prognosis, 
but also for cancer research in general.   
 
 
 
 
Table 1. TNM staging system and Dukes classification of CRC
Stage                                     Definition
T0
Tis
T1
T2
T3
T4
N0
N1
N2
M0
M1
Dukes A
Dukes B
Dukes C
Dukes D
* Weitz et al., 2005
Tumor invasion into other organs or through visceral peritoneum
No evidence of regional lymp node metastasis
Metastasis into 1-3 regional lymph nodes
Metastasis into ≥4 regional lymph nodes
Dukes stage 
No evidence of distant metastasis
Distant metastasis
Stage Grouping 
No evidence of primary tumor
Carcinoma in situ: intrepithelial or intramucosal
Tumor invasion into submucosa
Tumor invasion into muscularis propria
Tumor invasion through muscularis propria
Stage I: T1-2, N0, M0
Stage II: T3-4, N0, M0
Stage IV: Any T, Any N, M1
5-year survival (% )*
80-95
65-75
25-60
0-7
Stage III: Any T, N1-2, M0
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3.2 Colorectal tumorigenesis  
 
CRC develops from rapidly renewing epithelial cells lining the colon or rectum of 
the gastrointestinal tract. The epithelial cells form a single sheet with crypts 
protruding into the underlying connective tissue (Humphries & Wright, 2008). Stem 
cells are located at the base of the crypt, forming the stem-cell niche together with 
mesenchymal cells. The stem cells have the capability to regenerate all colonic cell 
types. In normal conditions, the epithelial stem cells receive homestatic signals from 
the surrounding mesenchymal myofibroblasts, including WNT-signaling ligands 
(Fevr et al., 2007). It is thought that the initial mutational event in CRC occurs in the 
epithelial stem cells, which then come to dominate the stem-cell niche through clonal 
expansion. The cells migrate up the crypt, fail to differentiate normally, and finally 
spread into the colonic epithelium (Humphries & Wright, 2008).  
 
It is now widely appreciated that CRC results from the accumulation of genetic and 
epigenetic alterations, which lead to the transformation of normal colonic epithelium 
to colorectal adenocarcinoma. The development of colorectal adenocarcinoma is 
characterized by a series of well-defined histopathological changes, each of which is 
accompanied by specific genetic alterations (Hanahan & Weinberg, 2000; Fearon & 
Vogelstein, 1990). A key feature underlying CRC development is genomic instability, 
which leads to the acquisition of multiple genetic alterations that then drive 
malignant transformation (Loeb, 1991; Fodde et al., 2001). It is thought that genomic 
instability occurs early in the tumorigenesis process, already during the initiation of 
adenoma formation (Shih et al., 2001; Nowak et al., 2002).  
 
CRC cells can acquire increased mutability of their genomes through several 
different molecular pathways. CRC tumors are usually divided into those with 
chromosomal instability (CIN) and those with microsatellite instability (MSI) 
(Aaltonen et al., 1993; Kinzler & Vogelstein, 1996) (Figure 3). Both of these pathways 
are effective mechanisms to remodel the genome in ways that favor evolution 
towards neoplasia. More recently, tumors have been subcategorized based on their 
mutation rate. The TCGA study recently described CRCs to be either non-
hypermutated or hypermutated based on the number of mutations on nucleotide 
level. Non-hypermutated cancers, which represent the large majority of CRCs (84%), 
are usually microsatellite stable (MSS) and show CIN (Cancer Genome Atlas 
Network, 2012). 
 
3.2.1 Chromosomal instability  
 
The CIN pathway reflects the classical adenoma-carcinoma sequence, the 
progressive accumulation of point mutations in genes such as APC, KRAS and TP53, 
in addition to frequent chromosomal losses and gains, especially losses on 
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chromosome arms 5q, 17p and 18q (Vogelstein et al., 1988; Fearon & Vogelstein, 
1990) (Figure 3). CIN is thought to arise at the very first steps of colorectal 
tumorigenesis, already in abberant crypt foci (ACF). ACFs develop before colorectal 
polyps and are the earliest detectable change of the adenoma-carcinoma sequence 
(Luo et al., 2006; Vogelstein et al., 1988). 
 
 
 
Figure 3. The stepwise progression of CRC. The main genetic alterations that drive tumorigenesis in 
both CIN and MSI tumors are shown. The schematic figure is modified from Knudson, 2001. See text 
for references.  
 
Biallelic inactivation of APC at 5q is the earliest mutational event observed in the 
adenoma-carcinoma sequence and seems to be required for the initiation of clonal 
evolution (Powell et al., 1992). Approximately 70-80% of sporadic CRCs show 
somatic inactivation of APC (Kinzler & Vogelstein, 1996; Polakis, 2007). A small 
subclass of tumors with wild-type APC shows mutations in other members of the 
WNT pathway, such as CTNNB1 (also known as β-catenin) (Morin et al., 1997). APC 
mutations can be found already at ACFs and are tightly associated with the degree 
of dysplasia of these lesions (Jen et al., 1994; Smith et al., 1992). The crypts in which 
the APC-mutant cells lie become slowly dysplastic as abnormal cells start to 
accumulate. Whether APC mutations occur on a background of genetic instability or 
triggers genetic instability remains an open question. Evidence suggests that APC is 
  
23 
mutated when cells are near-diploid rather than aneuploid (Michor et al., 2005; 
Fodde et al., 2001). Inactivation of APC seems to underlie both tumor initiation and 
promotion, since APC has also been reported to directly enhance mutation rates 
through chromosomal instability (Fodde et al., 2001).  
 
Additional mutations, such as activating mutations in KRAS, are required for 
adenoma growth and progression. Approximately 40% of CRCs show KRAS 
mutations with most mutations affecting codons 12 and 13 (Fearon & Vogelstein, 
1990; Wood et al., 2007; Vogelstein et al., 1988). Oncogenic KRAS has been shown to 
contribute to tumor progression at an early stage, during transition from 
intermediate to late adenoma (Lamlum et al., 2000). In KRAS wild-type tumors, the 
RAF–MAPK pathway might be activated by mutations in NRAS, EGFR (ERBB1) or 
ERBB2 (HER2) (Cancer Genome Atlas Network, 2012).   
 
For the polyps to progress into cancer, additional mutational events are required, 
such as loss of chromosome 17p, which is found in more than 75% of all CRCs 
(Rodrigues et al., 1990). The TP53 gene is thought to be the main target of 17p loss 
with somatic mutations, mostly missense mutations, frequently affecting the 
remaining TP53 allele. The inactivation of TP53 often coincides with transition of 
large adenomas into invasive carcinomas (Baker et al., 1990). Loss of 18q is another 
frequent event observed in CRCs. The genes that underlie molecular pathology are 
thought to be SMAD2 and SMAD4, mutated in a fraction of CRCs (Wood et al., 2007; 
Leary et al., 2008).  
 
It is estimated that the entire process from ACFs to invasive carcinomas takes 
between 20-40 years. During this period, there is a constant increase in CIN 
(Rajagopalan et al., 2003). The molecular basis behind CIN remains largely 
unexplained. It is thought that genes that regulate the formation of the mitotic 
spindle and proper alignment and segregation of chromosomes at mitosis may 
contribute to CIN (Grady, 2004; Barber et al., 2008), such as BUB1, MAD2 and APC 
(Cahill et al., 1998; Alberici & Fodde, 2006). 
 
3.2.2 Microsatellite instability  
 
A subset of CRC cancers have hypermutated genomes and show a so called 
“mutator phenotype”, due to defects in genes that function in the maintenance of 
genomic stability. These cancers are fairly stable on chromosomal level, with near-
diploid genomes; however, they show high mutation rates on nucleotide level. 
Hypermutated tumors have mutation rates of 10-100 per 106 bases, whereas non-
hypermutated tumors show mutation rates of less than 10 per 106 bases. The great 
majority of hypermutated tumors show microsatellite instability, driven by a 
defective mismatch repair system (Cancer Genome Atlas Network, 2012; Loeb, 1991). 
There are differences in the sequence of genetic events observed in hypermutated 
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versus non-hypermutated CRCs, which might imply that they undergo distinct 
pathways to tumorigenesis. Hypermutated CRCs generally show fewer mutations in 
APC, KRAS and TP53 and higher mutation frequencies in BRAF and TGF-beta 
pathway related genes (Cancer Genome Atlas Network, 2012; Jass, 2004) (Figure 3).   
 
Approximately 15% of CRCs develop through the microsatellite instability (MSI) 
pathway, which is driven by defects in the mismatch repair system. The defect can 
be inherited, which is the case in Lynch syndrome, or acquired, as in sporadic MSI 
tumors. In patients with Lynch syndrome, the MSI phenotype is caused by germline 
mutations in mismatch repair genes (mostly MLH1 and MSH2) (Aaltonen et al., 1993; 
Ionov et al., 1993; Thibodeau et al., 1993). Sporadic MSI CRCs are typically caused by 
epigenetic silencing of the MLH1 gene (Kane et al., 1997; Veigl et al., 1998). Previous 
studies have shown patients with MSI tumors to have better prognosis and a lower 
risk of recurrence than other CRCs (Watanabe et al., 2001; Van Schaeybroeck et al., 
2011). MSI tumors differ genetically and clinicopathologically from the rest of the 
CRC tumors. Common features of MSI tumors are proximal location, lymphocytic 
infiltration, poor differentiation and mucinous features (Vilar & Gruber, 2010).  
 
3.2.2.1 The mismatch repair system 
 
Microsatellites are repeated-sequence motifs, consisting of simple mono-, di-, tri- 
and tetranucleotide DNA repeats, found all across the genome in large numbers 
(Ellegren, 2004). These sequences are prone to mutations. Due to replication strand 
slippage, the DNA polymerase occasionally stutters while copying microsatellites, 
leading to longer or shorter versions of the repeats in the newly synthetized strand. 
These replication errors can be recognized and corrected by the MMR system. Base 
mismatches made by the DNA polymerase may also be erased by MMR proteins. 
The predominant components of the MMR machinery are MutSα, MutSβ and 
MutLα. First, MutSα (a heterodimer of MSH2 and MSH6) or MutSβ (a heterodimer 
of MSH2 and MSH3) locates the mismatch or the insertion-deletion loop. Second, 
MutLα (a heterodimer of MLH1 and PMS2) forms a complex with MutSα or MutSβ 
to subsequently activate the repair process (Boyer & Farber, 1998; Jiricny, 2006).  
 
3.2.2.2 Microsatellite instability target genes 
 
In cells with MMR defects, mismatches remain uncorrected, which ultimately results 
in a mutator phenotype. The great majority of the mutations in MSI tumors are 
passenger events with no effect on malignant growth. Occasionally, frameshift 
mutations that result in protein truncation, or other alterations in the protein 
product, target a crucial gene and provides the cell with a growth advantage (Loeb, 
1991; Boland et al., 1998). To distinguish real driver MSI target genes from 
passengers is challenging. Studies on non-coding repeats have revealed the 
background mutation frequency to be surprisingly high in MSI CRCs, with a strong 
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correlation to repeat type and length (Sammalkorpi et al., 2007). Several criteria have 
been suggested for the identification of real MSI target genes, such as high mutation 
frequency, biallelic inactivation, mutation in MSS cancers and supporting functional 
evidence (Boland et al., 1998). Examples of well-established target genes, with high 
mutation frequencies and robust functional evidence, are TGFBR2 (Markowitz et al., 
1995; Wang et al., 1995) and BAX (Rampino et al., 1997; Ionov et al., 2000).  
 
Frameshift mutations generally result in premature termination codons (PTC) and a 
truncated protein. For this reason the great majority of MSI target genes are thought 
to show loss of function effects. Translation of aberrant transcripts is usually 
inhibited by the nonsense-mediated decay (NMD) system that degrades mRNAs 
containing PTCs (Isken & Maquat, 2007). However, aberrant transcripts may escape 
the NMD-system, typically those with PTCs located at the very end of the mRNAs 
(Nagy & Maquat, 1998). 
 
3.2.3 The ultramutated phenotype 
 
Two recent studies identified a small novel class of hypermutated CRCs that result 
from exonuclease domain mutation (EDM) in POLE and POLD1 (Palles et al., 2013; 
Cancer Genome Atlas Network, 2012). POLE and POLD1 form the catalytic and 
proofreading subunits of the two central polymerases ε and δ, which replicate DNA 
(Nick McElhinny et al., 2008). The mutations can be inherited and lead to a rare 
condition termed polymerase proofreading-associated polyposis (PPAP). Affected 
individuals with such a condition have a high risk of multiple colorectal adenomas 
and carcinomas. Somatic mutations in POLE have been reported in CRCs as well as 
endometrial cancer. Currently, there is no proper evidence for the existence of 
pathogenic somatic POLD1 mutations. Both germline and somatic EDM mutations 
result in an “ultramutated” phenotype, with mutation rates of over 50 per 106 bases.  
Current evidence suggest these tumors to be of MSS type (Palles et al., 2013; Cancer 
Genome Atlas Network, 2012).  
 
3.2.4 Altered signaling pathways in colorectal cancer   
 
WNT signaling is a central pathway in embryogenesis and colonic homeostasis in 
the adult (Lin et al., 2008). In colorectal tumorigenesis, the initiating event is thought 
to be the activation of the WNT signaling pathway (Powell et al., 1992). In normal 
cells and in the absence of WNT ligand, APC associates with axin, glycogen synthase 
kinase 3 (GSK-3) and casein kinase 1 (CK1) to form a so-called -catenin 
destruction complex. -catenin is phosphorylated by this complex, resulting in  -
catenin ubiquitylation and subsequent proteosomal degradation (Polakis, 2002). 
However, in cells with mutations in members of the WNT signaling pathway, -
catenin accumulates and translocates to the nucleus. Once in the nucleus, it interacts 
with the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of transcription 
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factors to activate specific WNT target genes (Tetsu & McCormick, 1999), such as 
MYC and CCND1 (previous name cyclin D1) (Polakis, 2007; He et al., 1998).  
 
Another early event in CRC is increased signaling through the RAS/RAF/MEK/ERK 
pathway. The pathway is known to regulate proliferation and differentiation and is 
activated by stimuli such as growth factors and cytokines. Both activating KRAS and 
BRAF mutations are frequent oncogenic events in CRC tumors. The mutations lead 
to  constitutively activated proteins that promote cell proliferation by stimulating the 
RAS/RAF/MEK/ERK kinase cascade (Downward, 2003; Rajagopalan et al., 2003). 
Furthermore, alterations in the PI3-kinase (PI3K) pathway are also involved in CRC. 
The PI3K signaling pathway plays a key role in cancer proliferation, survival, 
motility, and metabolism. Mutations in PI3 kinase catalytic subunit alpha (PIK3CA) 
have been reported in approximately 32% of CRCs (Samuels & Velculescu, 2004; 
Samuels & Ericson, 2006). Ligand binding to epidermal growth factor receptor 
(EGFR) leads to the activation of both MAPK and PI3K pathway signaling. 
Treatment with cetuximab, a monoclonal antibody directed against EGFR, is 
routinely used in the clinic to improve patient survival. However, patients who have 
KRAS mutations are resistant to anti-EGFR antibody treatments (Misale et al., 2012).  
 
The loss of TP53-mediated pathways of apoptosis is another important event in the 
progression from adenoma to malignant tumor. The premalignant cell attempts to 
block the development of cancer through the functions of the TP53 protein. TP53 can 
cause cells to enter quiescence or apoptosis in the event that the machinery 
regulating cell proliferation is disturbed or the cell is exposed to different types of 
physiological stress. Mutations in TP53 are thought to occur relatively late in the 
development of colorectal tumors. Elimination of TP53 functions is greatly beneficial 
for the cancer cells and allows the cells to liberate themselves from its cytostatic and 
pro-apoptotic effects (Baker et al., 1990). In MSI CRCs, BAX is frequently inactivated 
(Rampino et al., 1997; Ionov et al., 2000). The pro-apoptotic protein BAX, which 
belongs to the bcl-2 family, functions as a key effector of the mitochondrial apoptotic 
pathways and participates in executing TP53-mediated apoptosis (Chipuk et al., 
2004; Miyashita & Reed, 1995). 
 
Alteration of the TGF- signaling pathway is critical for CRC progression and 
regulates epithelial proliferation, differentiation, invasion and apoptosis. The 
signaling cascade is initiated when TGF- ligands bind to a heterodimeric receptor, 
consisting of serine/threonine receptors I and II, on the cell surface. This activates the 
type I receptor kinase activity, which leads to phosphorylation of receptor-specific 
SMADs, such as SMAD2. Phosphorylated SMADs are then translocated to the 
nucleus by co-SMADs, such as SMAD4. In the nucleus, the SMAD complex, in 
concert with other DNA-binding proteins, activates the transcription of specific 
target genes, for example P21 and JUNB (Massagué, 2008). TGF- signaling pathway 
has a key role in controlling normal colonic epithelial homeostasis, and gene 
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alterations in this pathway are found both in sporadic and hereditary forms of CRC 
(Xu & Pasche, 2007).  
 
3.3 Inherited predisposition to colorectal cancer 
 
A comprehensive analysis on twins estimated that inherited factors contribute 35 % 
to the risk of developing CRC. The relative risk in siblings of patients affected by 
CRC is 2-3 fold (Lichtenstein et al., 2000). A large proportion of the inherited 
susceptibility to CRC is still unexplained. The distribution of allelic effects involved 
in complex traits, such as CRC, is predicted to be L-shaped. That is, a small number 
of alleles confer a large effect on the phenotype, whereas the great majority of alleles 
have individually a small effect. Rare risk alleles with large effects predominantly 
predispose individuals to hereditary cancer syndromes or more extreme 
phenotypes, e.g. very young age of onset (Bost et al., 2001; Mackay, 2001).  
 
3.3.1   Hereditary colorectal cancer syndromes 
 
Hereditary CRC syndromes (Table 2) are thought to explain less than 5 % of all CRC 
cases in the population (Aaltonen et al., 2007). CRC syndromes have classically been 
divided into two groups based on the presence or absence of gastrointestinal polyps. 
The polyposis syndromes, usually identified clinically, are defined by the presence 
of multiple polyps in the colon. The most common CRC syndromes are Lynch 
syndrome (also known as hereditary non-polyposis colorectal cancer, HNPCC) 
(Aaltonen et al., 1998; Lynch et al., 2006) and familial adenomatous polyposis 
(FAP)(Bodmer et al., 1987)  
 
3.3.1.1 Lynch syndrome  
 
Lynch syndrome, also referred to as hereditary non-polyposis colorectal cancer 
(HNPCC), is a dominantly inherited syndrome that accounts for approximately 2-
5 % of all CRC cases (Aaltonen et al., 1998; Lynch et al., 2006). In Lynch syndrome 
families multiple generations are usually affected with CRC at an early age (around 
45 years). Lynch syndrome patients develop tumors predominantly in the proximal 
colon and show an excess of synchronous and metachronous cancers. In addition, 
they have an increased risk for extracolonic cancers, such as endometrial, ovarian, 
gastric, and pancreatic cancers (Lynch, 1999; Aarnio et al., 1999). The penetrance of 
this syndrome is high; the lifetime risk of developing CRC is up to 80% in men and 
50% in women. In addition, women have approximately a 40-60% risk of developing 
endometrial cancer (Aarnio et al., 1995; Stoffel et al., 2009).  
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In 1993, the first susceptibility locus for this syndrome was mapped to 2p16 by using 
linkage analysis (Peltomäki et al., 1993) and the MSH2 predisposing gene was 
subsequently identified (Fishel et al., 1993; Leach et al., 1993). At the same time, 
Aaltonen et al. (1993) reported microsatellite instability in the tumors of the patients, 
linking Lynch syndrome to defective mismatch repair. Later, MLH1 was mapped to 
3p21 (Lindblom et al., 1993; Bronner et al., 1994; Papadopoulos et al., 1994), and the 
gene was subsequently shown to be the most important Lynch syndrome gene since 
it accounts for half of all cases (Peltomäki & Vasen, 2004). In Finland, there are two 
founder mutations in MLH1 that explain up to 60% of all Lynch syndrome cases 
(Nyström-Lahti et al., 1995; 1996). Other genes that have been linked to Lynch 
syndrome predisposition are MSH6 (Nicolaides et al., 1994) and PMS2 (Miyaki et al., 
1997). Patients carrying germline PMS2 mutations show clinical features of Turcot 
syndrome, characterized by familial aggregation of primary brain tumors in addition 
Table 2. Summary of hereditary CRC syndromes (modified from Kilpivaara and Aaltonen 2013)
Lynch Syndrome MLH1 DNA mismatch repair
(Lindblom et al., 1993; Bronner et al., 1994; 
Papadopoulos et al., 1994)
MSH2 DNA mismatch repair
(Peltomäki et al., 1993, Fishel., 1993; Leach et 
al., 1993) 
MSH6 DNA mismatch repair
(Miyaki et al., 1997)
PMS2 DNA mismatch repair
(Nicolaides et al., 1994)
Familial adenomatous polyposis APC Wnt signaling
Bodmer et al., 1987; Kinzler et al., 1991; 
Nishisho et al., 1991; Groden et al., 1991; 
Joslyn et al., 1991)
Peutz-Jeghers syndrome LKB1/STK11 Activation of AMPK-related kinases
(Hemminki et al., 1997; Amos et al., 1997; 
Hemminki et al., 1998)
Juvenile polyposis SMAD4
(Howe et al., 1998a; Howe et al., 1998b)
BMPR1A TGF-β signaling 
(Howe et al., 2001)
MYH-associated polyposis MUTYH DNA base excision repair
(Al-Tassan et al., 2002; Sieber et al., 2003)
Colorectal cancer and familial tooth 
agenesis
AXIN2 Wnt signaling
(Lammi et al., 2004)
POLD1
(Palles et al., 2013)
POLE Catalytic subunit of DNA polymerase ε
(Palles et al., 2013)
Polymerase proofreading-
associated polyposis
Signal trunsduction of the TGF-β 
superfamily and BMPs
Syndrome Gene(s) Gene Function
Catalytic and proofreading subunit of DNA 
polymerase δ1 
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to colorectal adenomas and carcinomas (Peltomäki, 2005).  
 
All the identified genes encode key components of the mismatch repair system, 
which consists of two main heterodimeric protein complexes: the MutL homologue 
(MLH1 and PMS2) and the MutS homologue (MSH2 and MSH6) (Kolodner et al., 
1995). A two-hit mechanism for DNA mismatch repair (MMR) gene inactivation has 
been shown to underlie the microsatellite instability (MSI) phenotype. Tumors from 
Lynch syndrome patients frequently show silencing of the MMR gene through LOH 
involving the wild-type allele (Parsons et al., 1993; Hemminki et al., 1994).  
 
 
 
Several international diagnostic criteria have been developed for Lynch syndrome, 
the foremost being Amsterdam I (Vasen et al., 1991), Amsterdam II (including 
extracolonic cancers) (Vasen et al., 1999) and Bethesda Guidelines (Rodrigues et al., 
1990; Umar et al., 2004) (Table 3). Since Lynch syndrome patients do not display any 
distinct clinical features, definite diagnosis can only be done by demonstrating the 
presence of a germline MMR mutation. Initial screening is often performed by 
analyzing MSI status in the tumors, combined with immunohistochemical staining 
(Lynch & Lynch, 2005). Bethesda guidelines were developed to identify individuals 
who should be tested for MSI. The Bethesda panel used for PCR-based MSI testing 
consists of five microsatellite markers; two out of five markers displaying length 
alterations is classified as MSI high (Rodrigues et al., 1990; Umar et al., 2004). Lynch 
syndrome patients should regularly be screened for colorectal adenomas and 
carcinomas by colonoscopy. It is recommended that patients undergo colonoscopy 
every 1-3 years starting from the age of 20-25 and any observed adenomas should be 
Amsterdam criteria II (Revised ICG-HNPCC Criteria)*
2) One should be a first-degree relative of the other two
3) At least two successive generations should be affected
4) At least one should be diagnosed before 50 years of age
5) FAP should be excluded in all CRC cases
Bethesda guidelines (Revised)**
Tumors from individuals should be tested for MSI in the following situations:
1) CRC diagnosed in a patient who is less than 50 years of age
2) Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors, regardless of age
4) CRC diagnosed in ≥ two first- or second degree relatives with HNPCC-related tumors, regardless of age
* 
Vasen et al., 1999,
 **
 Umar et al., 2004  
Table 3. Diagnostic criteria for Lynch Syndrome (HNPCC) and guidelines for MSI testing 
1) There should be at least three relatives with an HNPCC-associated cancer (CRC, endometrium, small 
bowel, ureter, or renal pelvis)
3) CRC with MSI histology (tumor inflitrating lymphocytes, Crohn's-like lymphocytic reaction, 
mucinous/signet-ring differentiation or medullary growth pattern) diagnosed in a patient who is less than 60 
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removed (Mecklin & Järvinen, 2005).  
 
3.3.1.2 Familial adenomatous polyposis 
 
Familial adenomatous polyposis (FAP) is an autosomal dominant disorder 
accounting for 0.5-1% of all CRC cases (Burn et al., 1991; Järvinen, 1992). The patients 
have very distinct clinical features, with hundreds of thousands of adenomas 
throughout the colon, and, if not treated correctly, will inevitably develop CRC at an 
early age (35-40 years). FAP patients have also an increased risk for other 
malignancies, including pigmented lesions of the retina, osteomas of the jaws, 
desmoid tumors and papillary thyroid carcinoma (Galiatsatos & Foulkes, 2006). 
Attenuated FAP is a subtype of classical FAP where patients display fewer colonic 
adenomas and usually at a later age (Lynch et al., 1995).  
 
FAP is caused by germline mutations in the APC gene on 5q21 (Bodmer et al., 1987; 
Kinzler et al., 1991; Nishisho et al., 1991; Groden et al., 1991, Joslyn et al., 1991). 
Many mutations have been identified, mostly nonsense and frameshift mutations, 
and there is a correlation between the genetic site of the mutations and the severity 
of the clinical manifestations (Rozen et al., 1999; Friedl et al., 1996). Also, reports 
have shown that the type of the second hit depends on the random first hit in the 
germline. It is believed that this occurs in order for the cell to ensure optimal WNT 
signaling levels (Lamlum et al., 1999; Albuquerque et al., 2002). Some cancers have 
been shown to harbor a third hit at APC, mostly through copy number gains and 
losses, in order to further fine tune the level of WNT activation (Segditsas et al., 
2009).  
 
FAP can be diagnosed clinically by the demonstration of > 100 colorectal adenomas. 
Genetic testing should be performed on all individuals showing classical polyposis 
to confirm the diagnosis. Also individuals with a family history of CRC or those with 
fewer adenomas, which might exhibit attenuated forms of the disease, should 
undergo genetic screening. Annual endoscopy is suggested for all mutation carries. 
Colectomy can be considered as a prophylactic treatment option (Järvinen, 2003). 
 
3.3.1.3 Other syndromes  
 
Other rare autosomal dominant CRC syndromes are Peutz-Jeghers syndrome (PJS) 
and Juvenile Polyposis (JP) that are both characterized by intestinal hamartomatous 
polyposis (Schreibman et al., 2005). PJS is caused by mutations in LKB1, encoding a 
serine/threonine kinase, located on chromosome 19q (Hemminki et al., 1997; Amos et 
al., 1997; Hemminki et al., 1998). Polyps of PJS patients are mostly found in the small 
intestine and the stomach, but also occur in the colon (Hemminki et al., 1998). 
Germline mutations in SMAD4 on 18q (Howe et al., 1998a; Howe et al., 1998b) and 
BMPR1A on 10q (Howe et al., 2001), members of the TGFβ-superfamily, underlie JP. 
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Polyps of JP patients are most prevalent in the colon and rectum; however, they may 
also affect the gastrointestinal tract. The age of onset is usually at teenage years 
(Howe et al., 1998).  
 
The MYH-associated polyposis syndrome is the only known CRC syndrome that is 
inherited in a recessive manner. Patients have a clinical phenotype similar to that of 
attenuated FAP patients; they display 10-100 colonic adenomas. The age of onset is 
typically around 46 years (Jo & Chung, 2005). The disease is caused by biallelic 
mutations in the base-excision repair gene MYH (also known as MUTYH) (Al-Tassan 
et al., 2002; Sieber et al., 2003). Also, monoallelic carriers have been reported to have 
a slight increase in CRC risk (Jenkins et al., 2006).  
 
Recently, a whole-genome effort discovered germline mutations in POLE and 
POLD1, which encode subunits of polymerase ε and δ, to underlie a rare novel 
syndrome termed polymerase proofreading–associated polyposis. Individuals with 
these mutations present multiple or large adenomas and adenocarcinomas (Palles et 
al., 2013). Heterozygous germline mutations in AXIN2 have been associated with a 
syndrome characterized by familial tooth-agenesis and predisposition to CRC 
(Lammi et al., 2004).  
 
3.3.2  Low- and moderate-penetrance alleles 
 
Inherited factors are estimated to play a role in approximately one-third of all CRC 
cases (Lichtenstein et al., 2000). High-penetrance mutations in known CRC 
predisposing genes explain only a small fraction of all cases with inherited 
susceptibility. Still today, the great majority of common CRC families, with only one 
first-degree relative affected, remain molecularly unexplained (Aaltonen et al., 2007). 
In Finland, around 11% of all patients with CRC have at least one first-degree 
relative with CRC (Salovaara et al., 2000). It is estimated that more than 60% of the 
excess familial risk remains molecularly unexplained (Lubbe et al., 2009; Salovaara et 
al., 2000). Genetic susceptibility to CRC underlies an unknown proportion of both 
familial and sporadic cases, and the division of cases into one of these two groups 
might be somewhat arbitrary. A few, hundreds or even thousands of predisposition 
alleles with different levels of risk and prevalence in the population are likely to 
collectively contribute to CRC susceptibility, accounting for both familial CRC cases 
as well as sporadic cases. In addition, modifier genes are also likely to influence the 
effect of genetic and environmental factors that contribute to CRC (la Chapelle, 
2004). 
 
Over the past 15 years, several strategies have been applied to identify additional 
predisposing variants. To date, several GWA studies on CRC have been performed. 
In total, common low-penetrance variants at approximately 20 genomic loci have 
been identified to be associated with CRC susceptibility. However, the loci detected 
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by GWA studies confer only a very modest effect on CRC risk, typically with odds 
ratios < 1.5 (Dunlop et al., 2012; 2013; Lubbe et al., 2012). For the great majority of 
loci the causative variants remain to be identified. One proposed mechanism of 
action is that the common variants would influence distal enhancer elements that 
regulate expression of key target genes (Pomerantz et al., 2009; Maurano et al., 2012). 
8q24, with the polymorphism rs6983267, is one of the most interesting CRC regions 
pinpointed by GWA studies (Tomlinson et al., 2007). At this region, a cancer-specific 
enhancer element has been identified that has been suggested to control the 
expression of the MYC oncogene (Tuupanen et al., 2009; Sur et al., 2012). Although, 
the effect of each common low-penetrance variant on CRC risk is small, an additive 
contribution has been observed. Studies have estimated that ten known low-
penetrance variants collectively explain less than 9% of the variance in familial CRC 
risk (Houlston et al., 2008; Niittymäki et al., 2010). 
 
The fact that common variants only explain a very small part of the variance in risk 
has led to alternative views of where to find the “missing heritability”. It has been 
proposed that rare variants of larger effects or common variants of very small effects 
might explain most of the variance in risk (Fletcher & Houlston, 2010; Gibson, 2011). 
Despite numerous candidate gene-screens, very few rare or low frequency variants 
of moderate penetrance have been identified for CRC. The majority of the proposed 
associations have not reached statistical significance and have been restricted by 
small sample sizes. Perhaps the only well-established example of a moderate-
penetrance variant is the APC I1307K that is carried by approximately 6 % of 
Ashkenazi Jews and confers a two-fold increase in CRC risk (Laken et al., 1997). 
 
Common CRC families, with only few affected cases, form an attractive patient 
group to search for additional predisposition variants. However, these families are 
usually too small for traditional linkage analysis and the variants are likely to be too 
diverse and rare to be detected by GWA studies. Advances in sequencing 
technologies have made exome and whole genome sequencing attractive approaches 
for identification of rare variants of varying penetrance. Recently, two small-scale 
exome sequencing efforts were conducted to search for novel CRC predisposition 
variants. In the limited sequence data, no variants were significantly associated with 
CRC. Both studies discovered a small number of genes that remain good candidates 
for CRC predisposition. No gene was identified as a candidate in both studies 
(Derycke et al., 2013; Smith et al., 2013). However, validation in larger sample sets 
and in other populations will be required for providing evidence for their 
association with CRC.  
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AIMS OF THE STUDY  
 
The main aim of this study was to provide a better understanding of the molecular 
mechanisms behind CRC predisposition and progression. The specific aims are 
listed below.  
 
Somatic mutation in MSI CRC (I-II) 
 
I. To characterize nonsense-mediated decay-escaping target genes with 
potentially oncogenic effects  
 
II. To identify novel oncogenes with mutation hot spots by exome sequencing  
 
Germline variants in familial CRC (III-IV) 
 
III. To study the role of 15 candidate cancer genes in familial CRC 
predisposition 
 
IV. To identify novel CRC susceptibility genes for familial CRC by utilizing                          
exome sequencing  
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MATERIALS AND METHODS 
 
The materials and methods used in this study are presented shortly below and are 
described in more detail in the original publications (referred to here by their roman 
numbers).  
 
1 Sample material  
 
Colorectal cancer patients (I-IV). A population-based material of 1,042 CRC patients 
was collected between 1994 and 1998 from nine Finnish central hospitals (Aaltonen 
et al., 1998; Salovaara et al., 2000). After 1998, sample collection was continued from 
two Finnish central hospitals and material from 472 CRC patients were available 
from this series (unpublished collection). The materials included normal and tumor 
tissue. Tumor samples have been studied for MSI, and in positive cases MLH1 and 
MSH2 have been Sanger sequenced. Detailed clinical information and pathological 
evaluations were available for all cases. Data on all first-degree relatives and their 
cancer occurrence were acquired from the Finnish Population Registry 
(http://www.vrk.fi) and the Finnish Cancer Registry (http://www.cancer.fi/ 
syoparekisteri/en/). Signed informed consent or authorization from the National 
Supervisory Authority for Welfare and Health was obtained for all samples. These 
efforts were reviewed and approved by the Ethics Committee and the Hospital 
district of Helsinki and Uusimaa (HUS).   
 
In study I, 100 MSI CRCs were selected for mutation screening.  The entire coding 
regions of highly mutated genes were screened in a set of 30 MSS CRCs. For 
clinicopathological associations, an additional set of 31 MSI CRC DNAs extracted 
from paraffin-embedded tumors obtained from Dr. Markus Mäkinen (Oulu 
University Hospital) were used. In study II, the exomes of 25 sporadic MSI CRC-
normal pairs were sequenced as a discovery set. For validation, a sample set of 86 
MSI tumors were available. Top-ranked genes were also screened in 75 MSS CRCs. 
In study III and IV, mutation screening was performed in familial CRC cases. All 
cases fulfilled the following criteria: 1) at least one CRC case in first degree relatives, 
2) negative for any known high-penetrance CRC gene and 3) availability of sufficient 
amount of DNA extracted from both tumor and normal tissue for respective studies. 
In study III, candidate gene screens were performed in 45 familial cases. Additional 
genotyping was performed in 967 population-matched CRC cases. In study IV, the 
discovery set included 96 independent familial CRC cases. The validation phase 
samples consisted of 954 population-matched cases. 
 
Population matched controls (III-IV). DNA samples from population matched 
anonymous blood donors were used as controls. These were obtained from the 
Finnish Red Cross Blood Transfusion Service.   
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Cell lines (I-II). MSI CRC cell lines DLD1, GP5D, HCA7, HCT116, HCT15, HCT8, 
HUTU80, LIM1215, L174T, RKO, SNUC2B, VACO5, CCL-231, LoVo, LS180 and 
human embryonic kidney cell line HEK293 were obtained from the American Type 
Culture Collection (AACR), the European Collection of Cell Culture (ECACC), or 
provided by Professor Ian Tomlinson. Commercially available Flp-In 293 T-Rex cells 
(Invitrogen) were also used in study II.  
 
2 Genetic analyses 
 
DNA (I-IV) and RNA (I-III) extractions. Genomic DNA from peripheral blood or 
fresh frozen tissue samples was extracted by a previously described non-enzymatic 
method (Lahiri & Nurnberger, 1991). Total RNA was extracted with the RNeasy Kit 
(Qiagen) or with TRIzol reagent (I-III; Invitrogen). cDNA synthesis was performed 
with M-MLV enzyme (Promega).  
 
In study I, laser-capture microdissection on malignant epithelial cells was performed 
prior to DNA extraction. Fresh-frozen tumor sections were prepared and stained 
with HistoGene LCM Frozen Section Staining Kit (Arcturus). Laser capture 
microdissection was performed on malignant epithelial cells with Arcturus 
Microdissection Instrument on CapSure LCM Caps (Arcturus). Genomic DNA was 
extracted by PicoPure DNA Extraction Kit (Arcturus).   
 
PCR and Sanger sequencing (I-IV). Sequencing primers were designed with 
Primer3 (http://biotools.umassmed.edu/bioapps/primer3_www.cgi) and Primer3 
Plus programs (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/) 
and reference sequences were obtained from the Ensembl (http://www.ensembl.org) 
and NCBI (http://www.ncbi.nlm.nih.gov) databases. Fragments were amplified with 
AmpliTaqGold enzyme (Applied Biosystems) or Phusion DNA polymerase 
(Finnzymes). PCR products were purified by using the ExoSAP-IT PCR purification 
kit (USB Corporation). Sanger sequencing was performed using BigDye v3.1 
sequencing chemistry (Applied Biosystems) and 3730xl DNA Analyzer (Applied 
Biosystems).  
 
Genotyping (III, IV). Genotyping was carried out by using the 7900HT Fast Real-
Time PCR System (Applied Biosystems) and massARRAY iPLEX Gold (Sequenom) 
and performed at the Institute for Molecular Medicine Finland (FIMM, University of 
Helsinki) and Estonian Genome Center (University of Tartu).  
 
Exome sequencing (II, IV). Coding regions were enriched with the Agilent 
SureSelect Human All Exon Kit v1 (Agilent) according to the manufacturer’s 
instructions. Sequencing of paired end short reads was performed on either Illumina 
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GAII or HiSeq platforms (Illumina) at Karolinska Institutet (Sweden) and at Finnish 
Institute for Molecular Medicine (FIMM) Genome and Technology Center. Raw 
sequencing data was run through an in-house analysis pipeline for exome 
sequencing data, which consisted of the following programs and tools: FASTQC 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc), Burrow-Wheelers Aligner 
(Li & Durbin, 2009), Picard Tools Markduplicates (http://picard.sourceforge.net), 
Samtools mpileup (Li et al., 2009), Genome Analysis Toolkit IndelRealigner 
(McKenna et al., 2010) and Genome Analysis Toolkit UnifiedGenotyper (McKenna et 
al., 2010). In addition, an in-house script was utilized to remove 3’ ends with high 
adapter similarity. Exome data was analyzed with a visualization and comparative 
analysis tool developed in the laboratory (unpublished) as described below.  
 
In study II, somatic mutations from 25 MSI CRC exomes were extracted by filtering 
the data against exome data from the respective normal tissues. Somatic sequence 
data was control filtered against data from the 1000 Genomes Project (Phase 1 release 
(1000 Genomes Project Consortium et al., 2012)), population matched exome control 
data (n=69) and data from the Database of Single Nucleotide Polymorphisms (Build 
132, www.ncbi.nlm.nih.gov/SNP) to further exclude germline variants. Subsequent 
analysis focused on non-synonymous missense variants forming potential mutation 
hot spots. Sanger sequencing was performed on all missense variants that located to 
the same or adjacent codons in at least two tumors.  
 
In study IV, the germline exome data from 96 familial CRC cases was analyzed for 
putative loss-of-function variants, including nonsense, frameshifting insertions and 
deletions, and splice-site variants. Variants were filtered against population matched 
exome control data (n=212) and data from the 1000 Genomes Project (Phase 1 release, 
(1000 Genomes Project Consortium et al., 2012)) with a MAF threshold of 0.001. 
Subsequent analysis was focused on genes with putative loss-of-function variants in 
at least two cases. These were further validated by Sanger sequencing. 
 
Expression microarray analysis (I). A previously characterized Human Genome 
U133A 2.0 oligonucleotide microarray (Affymetrix) dataset was available for this 
study (Andersen et al., 2009). RNA samples from 73 MSI CRCs and 10 normal 
colonic mucosa samples were analyzed. Analysis was limited to genes that were 
overexpressed in MSI CRCs compared to normal mucosa (mean fold change 2). 
 
Quantitative real-time PCR (II). Relative expression of mRNA was determined with 
TaqMan chemistry and the ABI Prism 7500 sequence detection system (Applied 
Biosystems). Assays for ZBTB2 (assay ID, Hs00535603_m1), PSRC1 
(Hs00364137_m1), RANBP2 (Hs01108576), and Human B-actin (4310881E) were used 
(Applied Biosystems). 
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3 Protein analyses  
 
Western blot analysis (I, II). Proteins (25-30ug) were fractioned by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis in a 7.5% Tris-HCL polyacrylamide gel 
and transferred to a nitrocellulose filter. Immunoblots were incubated with primary 
antibodies: anti-mouse TTK (H00007272-M01; Abnova) and anti-human influenza 
hemagglutinin (HA-11; Covance) at dilutions 1:500 and 1:10,000, respectively. 
Antibodies against alpha-tubulin (T5168; Sigma-Aldrich) and glyceraldehyde-3-
phosphate dehydrogenase (ab9485; Abcam) were used as loading controls. 
Appropriate horseradish peroxidase conjugated secondary antibodies were used 
followed by enhanced chemiluminescence detection.  
 
Immunohistochemistry (I). Paraffin-embedded tumor sections were stained with a 
monoclonal antibody against human TTK (Zymed Laboratories Invitrogen) for 2 
hours at a dilution of 1:50. Tris-EDTA buffer (pH 9) was used in the heat-induced 
epitope retrieval. Detection was performed with anti-Mouse/Rabbit PowerVision 
Poly-HRP IHC Detection System (Leica Biosystems Newcastle Ltd).  
 
Immunofluorescence (II). Fixed cells were stained with the anti- HA antibody 
(Covance) and secondary Alexa Fluor-488-conjugated goat anti-mouse IgGs 
(Invitrogen, Life Technologies) at dilutions 1:10,000 and 1:500, respectively. Nuclei 
were also stained with Hoechst stain solution (Sigma-Aldrich). The Zeiss Axioplan 2 
upright epifluorescence microsope was used for imaging.  
 
Liquid chromatography-mass spectrometry (II). Large-scale protein-complex 
analysis was performed on ZBTB2 and PSRC1, both wild-type and mutant forms. 
Both sample preparations and liquid chromatography-mass spectrometry runs were 
performed in the Institute of Biotechnology (Finland) in collaboration with docent 
Markku Varjosalo. Single-step affinity purification was performed as described 
previously (Varjosalo et al., 2013). In short, for each pulldown, a cell pellet deriving 
from 5 × 15–cm fully confluent dish was lysed for 10 min on ice in 5 mL HNN lysis 
buffer. Replicates were done for each pulldown. Bait proteins were tagged with a 
Twin-Strep-tag (“SH”), and strep-Tactin Sepharose beads were used to isolate the 
bait proteins. The beads were transferred to a Bio-Spin chromatography column 
(Bio-Rad) and washed with 3 × 1 mL HNN buffer and 3 × 1 mL HNN buffer without 
detergent and inhibitors, and bound proteins were natively eluted into fresh 
Eppendorf tubes. Mass spectrometry runs were performed on an Orbitrap Elite ETD 
mass spectrometer (Thermo Scientific) with Thermo Scientific nLCII nanoflow 
system (Thermo Scientific), as described in Varjosalo et al. (2013). Proteome 
Discoverer software (Thermo Scientific) was utilized both in peak extractions and 
subsequent protein identification. The data analysis program SEQUEST was used to 
search for calibrated peak files against databases of human protein sequences 
  
38 
(http://fields.scripps.edu/sequest/). 
 
4 Cell culture studies  
 
Mutagenesis and cloning (I, II). In study I, wild-type and mutant TTK cDNA were 
cloned into pEGFP-C2 vector (Clontech) with an N-terminal green fluorescence 
protein (GFP) tag. Plasmids were transfected into HEK293 cells with 
Lipofectamine2000 (Invitrogen) according to the manufacturer’s instructions. For 
localization experiments, paclitaxel (Molecular Probes) was added 24h after 
transfection (20nM) and cells were subsequently fixed after 6h.  
 
In study II, site-directed mutagenesis was performed according to manufacturer’s 
protocols with QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) on 
cDNA clones (PSRC1; RG221688, ZBTB2; RG204198, OriGene) to generate mutants. 
The Gateway cloning system (Invitrogen, Life Technologies) was used to clone wild-
type and mutant cDNAs into pDONR21 vector (Invitrogen, Life Technologies). This 
was done according to the manufacturer’s instructions. Expression vectors for 
tetracycline-controlled expression of streptavidin-binding peptide hemagglutinin 
(HA)-tagged version of the cDNA were produced. An LR recombination was done 
between the entry clones and the destination vectors: pcDNA5/FRT/TO/SH/GW (N-
terminally tagged) and pcDNA5/FRT/TO/cSH (N-terminally tagged). Destination 
vectors were designed in the laboratory of Dr. Markku Varjosalo (Varjosalo et al., 
2013).  
 
Generation of stable and inducible cell lines (II). Flp-In 293 T-REx cells 
(Invitrogen) were cultured as described by the manufacturers. Cells were co-
transfected with the expression vectors (pcDNA5/FRT/TO/SH/GW and 
pcDNA5/FRT/TO/cSH) and the pOG44 vector (Invitrogen) using Fugene transfection 
reagent (Roche). Hygromycin (100 g/mL) was added two days after transfection for 
selection. Positive and isogenic clones were collected and amplified after 2-3 weeks. 
Inducible expression, by incubating the cells with doxycycline (1 g/mL, Sigma-
Aldrich) for 24h, was verified by Western blot analysis and immunofluorescence.  
 
Cell proliferation assay (II). Stable and inducible Flp-In 293 T-REx cells with SH-
tagged ZBTB2 and PSRC1 (both wild-type and mutant), were cultured according to 
the manufacturer’s instructions (Invitrogen, Life Technologies). After one week, cells 
(2.0 x 105) were plated on 6-well plates with media containing 1 µg/mL doxycycline 
(Sigma-Aldrich). Four replicates were done for each of the construct-containing Flp-
In 293 T-REx cell lines. Every three to four days, cells were manually counted and re-
plated, for a total of 13 days. The experiment was repeated once.  
 
Paclitaxel sensitivity assays (I). The sensitivity of four MSI CRC cell lines LoVo, 
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HCT116, DLD1 and HCT8 to paclitaxel was analyzed with IncuCyte live-cell 
imaging system (Essen Instruments) and colony formation assay. MSI CRC cell lines 
were cultured on 48-well plates and filmed once per hour with IncuCyte live-cell 
imaging system (Essen Instruments) for 96h. Paclitaxel was added after 21h (10, 25 
and 50nM). Cell confluence and morphology were analyzed from the time-lapse 
movies. For the colony formation assay cells were grown on 12-well plates and 
paclitaxel was added (1, 5, 10 and 25 nM) after 48h incubation. Drug-containing 
media was changed daily and the cells were incubated for eight days in total. Cells 
were fixed (96% methanol) and stained with 0.05% Crystal Violet (Sigma Aldrich). 
Imaging and quantifications of colonies were done with GeneGenius bio imaging 
system, GeneSnap and GeneTools softwares (Syngene). In both assays, DMSO was 
used as negative control. 
 
5 Statistical analyses and computational tools 
 
In silico variant effect predictions (II, III). The following programs were used to 
predict the functional consequence of the identified germline variants and somatic 
mutations: the Ensembl Variant Effect Predictor (McLaren et al., 2010), SIFT 
(http://sift.jcvi.org/), Polyphen (http://genetics.bwh.harvard.edu/pph/index. 
html), PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/), NetGene2 
(http://www.cbs.dtu.dk/services/NetGene2/) and BDGP Splice Site Prediction tool 
(http://www.fruitfly.org/seq_tools/splice.html). Multiple DNA alignments were 
generated with Multiz alignments (Blanchette et al., 2004). EMBOSS Transeq was 
used to translate genomic sequences into corresponding peptide sequences and the 
protein sequences were aligned with T-Coffee (http://www.ebi.ac.uk/tools/). 
Computational tool for microsatellite-containing genes (I). A computational tool 
was created that predicted NMD-escape whenever a frameshift-induced termination 
codon located 55 bps upstream of the last exon-exon junction or in the last exon 
(Nagy & Maquat, 1998). All transcripts with mutated mononucleotide repeats (6-10 
bp) that were predicted to escape NMD were identified from Ensembl (Homo 
sapiens 45_36g; www.ensembl.org). Further analysis focused on overexpressed 
genes in MSI CRC. 
 
Protein interactome analysis (II). The mass spectrometry data was analyzed with 
Ingenuity Pathways Analyses (www.ingen.com) software. Identified proteins were 
mapped into relevant groups for molecular and cellular function based on 
Ingenuity’s knowledge base. Heat maps were performed with R.   
 
Statistics (I, II, IV). Chi-squared test was utilized to calculate differences between 
groups of patients or samples. Bonferroni’s correction for multiple testing was used 
to obtain P-values for clinicopathological associations (I). In study II, a randomized 
test of goodness-of-fit was used to test whether the number of mutation hot spots 
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observed in the exome data differed from that expected. The mutations observed in 
the exome data were redistributed randomly in the exome according to previously 
reported nucleotide frequencies and the mutation hot spots were counted 
(Greenman et al., 2007). The process was repeated and a null distribution was 
obtained. P value was determined by comparing observed counts to the null 
distribution. The same was done for the hot spot mutation frequencies observed in 
the validation set. The    –log of P-values for molecular and cellular functions based 
on Ingenuity’s knowledge base were calculated by Fisher exact test. In study IV, 
exact binominal test was used to calculate P-values for wild-type allele losses. 
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RESULTS 
 
1 TTK is frequently mutated in microsatellite-unstable colorectal 
cancer  
 
1.1 Identification of TTK mutations  
 
We combined microarray expression profiling of MSI CRCs with a bioinformatics 
search and identified 330 overexpressed genes that were predicted to escape NMD 
after a deletion in a microsatellite repeat.  Sanger sequencing was done in 30 MSI 
CRCs for repeats in 258 genes. The great majority of the repeats showed low somatic 
mutation frequency (7%). Four genes were mutated in >20% of the 100 MSI CRCs 
analyzed: TTK (TTK protein kinase, 67%), TMEM97 (Transmembrane protein 97, 39%), 
ARS2 (Arsenite-resistance protein 2, 33%), LENG8 (Leukocyte receptor cluster member 8, 
31%). Only TTK had a mutation frequency higher than expected by chance when 
compared to non-coding identical control repeats and was thus studied further.   
 
1.2 TTK mutation spectra in colorectal cancer 
 
The last exon (22) of TTK has a complex repeat that consists of A9-G4-A7 repeats. 
The mutation frequency was 59% at this locus in a total set of 179 MSI CRCs 
analyzed (105/179). The complex repeat (A9-G4-A7) was anticipated to be more 
unstable than a normal mononucleotide repeat alone, thus, the genome was searched 
for identical non-coding complex repeats to assess the background mutation 
frequency at such loci. TTK was shown to harbor mutations significantly more often 
than compared to identical control repeats (105/179 in TTK vs. 50/139 in controls, 
P=9.5 x 10-5).  
 
Table 4.TTK frameshift mutations in MSI CRC 
Exon (repeat type) MSI CRCs Mutation (coding) 
2 (A5) 1/100 c.86delA 
5 (A7, A7) 21/279 (12%) c.484delA, c575delA 
20 (A4) 1/100 c.2331delA 
22 (A9-G4-A7) 105/179 (59%) c.2560delA* 
*The most frequent mutation at the repeat  
   
Additional TTK frameshift mutations were observed at repeats in exons 2, 5 and 20 
(Table 4). All mutations identified were heterozygous. Exon 5 deletions were 
enriched in exon 22 wild-type tumors (P=0.017). Exons 5 and 22 were also analyzed 
for mutations in 12 MSI CRC cell lines and repeat mutations were found at 
frequencies 25% and 58%, respectively (see Table II in the original publication). 
Mutation hot spots in exons 5 and 22 were also screened in 848 MSS CRCs and three 
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tumors showed frameshift mutations in exon 22.  
 
1.3 Expression and localization of TTK 
 
Western blot analysis showed the most common TTK frameshift mutation 
(c.2560delA) to result in elongation of the peptide by 34 amino acids in two 
heterozygous mutant cell lines, LoVo and HCT116 (see Figure 4A). 
Immunohistochemical stainings of TTK revealed no difference in localization or 
intensity between wild-type and mutant MSI CRC tumors (see Figure 1D in original 
publication). GFP fusions of the wild-type and mutant (c.2560delA) TTK proteins 
were expressed in HEK293 cells and showed similar localization; TTK localized at 
the cytoplasm and at the kinetochores (see Figure 3 in the original publication). 
 
 
 
 
                                                      
 
 
Figure 4. Functional studies on mutant TTK. (A) The elongated TTK peptide (arrow) was detected in 
LoVo and HCT116 MSI cell lines with the c.2560delA mutation. (B) The mutant cell line HCT116 was 
incubated with the microtubule-stabilizing drug paclitaxel (10nM) and DMSO, as control, to test the 
spindle-assembly checkpoint arrest. Examples of live-cell images shown from time-points 24h, 48h 
and 72h. Cells cultured with paclitaxel arrested in the checkpoint and typically died from this arrest.    
 
1.4 TTK and the spindle assembly checkpoint 
 
Two wild-type (DLD1 and HCT8) and two mutant MSI CRC cell lines (LoVo and 
HCT116) were treated with the microtubule-stabilizing drug paclitaxel and analyzed 
with IncuCyte live-cell imaging and colony formation assay. When cells were 
cultured in the presence of paclitaxel, a reduction in confluence was observed by 
live-cell imaging in the mutant cells. Both LoVo (figure not shown) and HCT116 cells 
(Figure 4B) begun to arrest in mitosis and later mostly died from the arrest, 
suggesting that the checkpoint response is intact in mutant MSI CRC cells. In the 
colony formation assay, viability was drastically reduced for HCT116 when treated 
with paclitaxel, providing further evidence that the checkpoint response is 
 
 
 
TTK 
 
 
 
Tubulin 
A                                                                B 
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functional (see Figure 4 in the original publication). In the LoVo cells, colony 
formation was insufficient for quantification even in the control and was therefore 
excluded.  
 
2 Novel candidate oncogenes in microsatellite-unstable colorectal 
cancer  
 
2.1 Identification of fifteen candidate oncogenes with mutation hot spots 
 
We systematically searched for novel oncogenes by exome sequencing 25 MSI CRCs 
and respective healthy tissues. All cases were sporadic. The exome data was 
searched for potential hot spot mutations, in other words, missense mutations in at 
least two tumors hitting the same or adjacent codon. As expected, hot spot mutations 
in known MSI CRC oncogenes were identified: BRAF (V600, 32%, 8/25), KRAS (8%, 
2/25) and CTNNB1 (8% 2/25). In addition, novel potential mutation hot spots were 
observed in 30 genes in the exome data. Mutation hot spots in 15 genes were 
confirmed by Sanger sequencing (Table 5). In the discovery set of 25 MSI tumors, 
ITGA7 displayed three hot spot mutations, and the rest of the genes showed two.  
 
            
 
Table 5. Novel candidate oncogenes in MSI CRC 
ADAR adenosine deaminase, RNA-specific Tyr1173, Arg1172
DCAF12L2 DDB1 and CUL4 associated factor 12-like 2 Arg335
GLT1D1 glycosyltransferase 1 domain containing 1 Ala157, Val158
ITGA7 integrin, alpha 7 Ala970, Arg969
MAP1B microtubule-associated protein 1B Pro480, Ala481
MRGPRX4 MAS-related GPR, member X4 Ser114, Ala115
PSRC1 proline/serine-rich coiled-coil 1 Arg136, Thr135
RANBP2 RAN binding protein 2 Arg945
RPS6KL1 ribosomal protein S6 kinase-like 1 Thr55, Ala54
SNCAIP synuclein, alpha interacting protein Arg499
TCEAL6 transcription elongation factor A (SII)-like 6 Pro101, Arg100
TUBB6 tubulin, beta 6 class V Ala231, Thr232
WBP5 WW domain binding protein 5 Arg46, Glu47
VEGFB vascular endothelial growth factor B Val54, Pro55
ZBTB2 zinc finger and BTB domain containing 2 Arg262, Arg261
PSRC1 c.404G>A (x2), c.407C>T, c.406G>A (x2) 5/109, 4.6%
RANBP2 c.2833C>T (x2), c.2834G>A (x2) 4/109, 3.7%
ZBTB2 c.781G>A (x3), c.784G>A  4/106, 3.8%
* Gene descriptions taken from HGNC (http://www.genenames.org)
** In brackets the number of times the mutation was identified
Candidate 
oncogene
Mutation hot spot site 
(amino acid)
Gene description*
Genes with 
mutations in the 
validation set
Identified Mutations (cDNA)**
Overall frequency of hot 
spot mutations 
  
44 
Interestingly, only three genes showed additional hot spot mutations in the 
validation set: ZBTB2, RANBP2 and PSRC1 with mutations frequencies of 2.5% (2/81 
MSI CRCs), 2.4% (2/84) and 3.6% (3/84), respectively. The overall frequencies of hot 
spot mutations were 3.8% (4/106 MSI CRCs), 3.7% (4/109) and 4.6% (5/109) for 
ZBTB2, RANBP2 and PSRC1, respectively (Table 5). In Figure 5, the domains and 
missense mutation sites of ZBTB2, RANBP2 and PSRC1 proteins are depicted. 
Mutation sites in ZBTB2 and RANBP2 were highly conserved across species (see 
Figure 1 and Supplementary Figure 1 in the original publication). No hot spot 
mutations were identified in 75 MSS CRCs and 12 MSI CRC cell lines in these three 
genes. Overexpression of ZBTB2, RANBP2 and PSRC1 was observed in mutation-
positive tumors (in 2/2, 2/2 and 2/4 tumors, respectively) compared to respective 
normal tissue (see Supplementary Figure 1 in the original publication).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic diagram of the domains and missense mutations of ZBTB2, RANBP2 and PSRC1. The red 
line indicates the region that was screened in the validation set samples. Data from Seshagiri et al., 2012 and 
Cancer Genome Atlas Network, 2012 were searched for the same missense mutations identified here (white 
arrow). Sequencing data from other cancer types in the cBioPortal for Cancer Genomics 
(http://www.cbioportal.org/public-portal/) were searched for our hot spot mutations (black arrow). Information 
on structural and functional domains was obtained from cBioPortal for Cancer Genomics 
(http://www.cbioportal.org/public-portal/) and the Ensembl database (http://www.ensembl.org). BTB: BR-C, ttk 
and bab; POZ: Pox virus and Zinc finger; Zf-CH2H: Zinc finger C2H2 type; TPR-1: tetratricopeptide repeat 
domain 1; Zf-RanBP: Zn-finger in Ran binding protein; Ran_BP1: Ran binding domain; IR1-M:internal repeat 
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domain; C-PPIase: Cyclophilin-like peptidyl-prolyl cis-trans isomerase domain; GTSE1-N: G-2 and S-Phase 
Expressed 1; Aa: Amino acid. 
 
2.2 Functional studies on mutant ZBTB2 and PSRC1 proteins 
  
Next, we wanted to investigate the impact of the hot spot mutations on protein 
functions by mass spectrometry analysis and long-term cell proliferation analysis. 
For these experiments, we generated stable Flp-In 293 T-Rex cells with inducible 
expression of both wild-type and mutant ZBTB2 and PSRC1. No construct was 
available for RANBP2, due to its large size ( 12kb). Mass spectrometry analysis of 
ZBTB2 and PSRC1, both wild-type and mutant forms, was performed to 
systematically map all protein interactions. The protein interactomes consisted of 
several known cancer-associated proteins (data not shown) and proteins with 
molecular functions relevant to tumorigenesis (see Figure 6). Moreover, the hot spot 
mutations in ZBTB2 and PSRC1 were shown to alter the protein interactomes (see 
Supplementary Figures 2C and 2D in the original publication).  
 
 
                    
 
 
Figure 6. Interactomes of ZBTB2 and PSRC1. The pie diagrams show the distribution of ZBTB2 and 
PSRC1 interaction proteins according to their top five molecular and cellular functions. Numbers 
indicate the number of interaction proteins in each group. Data on protein functions were obtained 
with Ingenuity Pathways Analyses software. 
 
Next, we wanted to study whether the mutant proteins caused an increase in cell 
proliferation. Results from the long-term cell proliferation assay showed a clear 
increase in proliferation in cells with the hot spot mutation (Arg261Trp) in ZBTB2 
(Figure 7). No difference in proliferation was observed between wild-type and 
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mutant forms of PSRC1.  
 
        
 
3 Mutational profiles of fifteen candidate cancer genes in familial 
colorectal cancer 
 
A systematic sequencing study conducted by Wood et al. (2007) identified 140 cancer 
candidate genes (CAN genes) somatically mutated in CRC. In our effort, the entire 
coding regions of 15 top-ranked CAN genes (see Table 6) were screened for somatic 
mutations and germline variants in 45 familial CRC cases. Six of the genes were  
 
 
 
 
Table 6. Mutational profiles of fifteen CAN genes in familial CRC
Mutation frequency* Mutation types 
PIK3CA 8/45, 18% Missense 
FBXW7 8/45, 18% Missense (7)  Nonsense (1)
CSMD3 2/45, 4.5% Missense c.4045T>G, p.F1349V 0/865
TNN 0/45
NAV3 0/45
EPHA3 0/45
MAP2K7 0/45
EPHB6 1/45, 2% Missense c.961G>C, p.A321P 0/843
ADAMTSL3 0/45
GUCY1A2 0/45
SMAD2 1/45, 2% Missense
OR51E1 0/45
LAMA1 0/45
c10orf137 0/45 c.827T>C, p.I291T 0/876
TCF7L2 2/45, 4.5% Missense, Splice site
**Only germline variants that were absent in controls are listed here
Gene 
Somatic mutations Population 
matched controls 
Germline 
variants** 
* Silent mutations were not included in the counts 
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Figure 7. Mutant ZBTB2 showed 
increased cell proliferation. An increase 
in cell proliferation was observed for the 
CRC-associated mutant form of ZBTB2 
(Arg261Trp) in HEK293 cells. Error bars 
depict the standard error of the mean. 
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somatically mutated in the familial CRC cases with a total of 22 non-synonymous 
mutations. The most frequently somatically mutated genes were phosphatidylinositol-
4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA, 18%) and F-box and WD repeat 
domain containing 7 E3 ubiquitin protein ligase (FBXW7, 18%) with most mutations 
locating at previously reported mutation hot spots. In the germline, three novel 
missense variants were identified in CUB and Sushi multiple domains 3 (CSMD3), 
chromosome 10 open reading frame 137 (C10orf137) and EPH receptor B3 (EPHB3). None 
of them were present in the 890 population-matched controls (Table 6). The 
respective tumors did not show LOH. Only the variant in C10orf137 was shown to 
segregate in the family. Currently, the functions of CSMD3 and C10orf137 have been 
poorly defined, and further studies are required to clarify their potential role in 
cancer. EPHB3 encodes for an ephrin receptor, which belongs to the Eph receptor 
tyrosine kinase family, and has been suggested to act as a tumor suppressor in CRC 
tumorigenesis (Battle et al., 2005).  
 
4 Eleven novel candidate susceptibility genes for familial colorectal 
cancer 
 
Exome sequencing was conducted on germline DNA from 96 independent familial 
CRC cases. As part of previous efforts (Aaltonen et al., 1998; Salovaara et al., 2000), 
all cases had been shown to be mutation negative for any known high-penetrance 
CRC predisposing gene by standard clinical and molecular approaches. To further 
exclude such cases, the exome data was first analyzed for mutations in the following 
known high-penetrance CRC genes: MLH1, MSH2, MSH6, PMS2, APC, MUTYH, 
SMAD4, BMPR1A, STK11 (also known as LKB1), PTEN, AXIN2, POLE and POLD1. 
Exome sequencing revealed no clear predisposing mutation in these genes. Next, we 
searched for novel candidate predisposing genes with rare putative LoF variants 
(nonsense, frameshift and splice-site). A detailed presentation of the steps taken in 
this study and the number of variants at each step is presented in Figure 8.  
 
In total, we identified 11 novel candidate predisposing genes with putative LoFs 
(Table 7). Nine genes showed LoFs in 2/96 familial cases and two genes showed LoFs 
in 3/96 familial cases. All variants had a MAF of  0.001 in Finnish population 
matched controls (Table 7). We also examined variant frequencies in Exome variant 
server (http://evs.gs.washington.edu/EVS/) and 3/14 variants were found, however at 
very low frequency (MAF < 0.0003). This data set was not available at the time of 
data analysis and was therefore not included in the initial control filtering step. 
Interestingly, the splice-site variant in PRADC1 was also identified in a 
nonsyndromic Finnish CRC patient diagnosed at the age of 36 years (unpublished 
data). The patient had no first-degree relatives with CRC. The candidate CRC 
predisposing loci were also searched for missense variants. Five missense variants, in 
five genes, were identified and these were all rare in population matched controls 
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(MAF < 0.001) (Table S3 in the original publication). None of them were predicted to 
have a damaging effect on protein function by either of the prediction programs 
used.   
 
 
 
Loss of heterozygosity (LOH) was examined in the tumor tissue of cases carrying 
candidate predisposing variants. Altogether, seven LOH events were observed 
(Table 7) and the wild-type allele was lost in all seven occasions (P= 0.0078). Variants 
in genes showing LOH in the tumor tissue were genotyped in an independent 
population matched set of 954 CRC cases and 586 controls. Genotyping results are 
presented in Table 6, in the column termed validation phase samples. Genotyping 
was not successful for c.389_390insA in PSPH. Segregation analysis was performed 
whenever possible and results are presented in Table 7 and pedigrees are shown in 
the original publication (Figure 3 and Figure S1).  
  
Table 7. Eleven novel candidate susceptibility genes for familial CRC
UACA p.Q1116X 2/96 1/522 2/862 1/550 3/4
UACA p.QR1292X 1/96 0/494 1/823 0/550 0/2
SFXN4 fs 3/96 1/502 0/3 yes
TWSG1 p.Q41X 2/96 0/494 0/886 0/545 2/2 partial
PSPH fs 2/96 1/502 1/2
NUDT7 p.Y37X 2/96 0/494 0/2
ZNF490 p.R350X 2/96 0/491 1/877 0/551 1/3 no
PRSS37 sp 1/96 0/491 0/1
PRSS37 p.W138X 1/96 0/489 0/1
CCDC18 sp 1/96 0/492 0/1
CCDC18 p.S1109X 1/96 0/475 0/1
PRADC1 sp 2/96 0/482 0/2 yes
MRPL3 sp 2/96 0/487 0/2
AKR1C4 fs 2/96 0/491 0/1 yes
*fs  = frameshift insertion and deletion variant, sp= splice site variant
** Control counts include both exome data and Sanger sequenced controls
Discovery phase samples Validation phase samples
Gene 
Variation 
(Amino acid)*
Familial 
cases 
Finnish 
population 
matched 
controls** 
Finnish 
population 
matched 
cases 
Finnish 
population 
matched 
controls 
Loss of 
wt 
allele 
Segregation
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 Figure 8. Summary of the overall study design used in study IV. MAF = minor allele frequency 
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Study subjects 
Finnish population-based series of 1,042 CRC cases 
Additional Finnish series of 472 CRC cases 
Exome sequencing of 96 independent familial CRC cases 
76,487 nonsynonymous variants 
3,654 truncating variants 
Variant control filtering (MAF > 0.001) 
Population matched control exome data (N=212) 
1000 Genomes data 
 
Genes with truncating variants in  2 cases 
2,090 truncating variants 
588 truncating variants 
(422 frameshift, 115 nonsense, 51 splice site) 
Manual exclusion 
Systematic sequencing errors and mapping errors 
46 truncating variants 
Sanger validation 
23 truncating variants in 18 genes 
Sanger sequencing of population matched controls (n=310) 
Remove variants with MAF > 0.001 in entire set of population 
matched controls (control exome data + Sanger sequenced controls) 
 
14 truncating variants in 11 genes 
LOH analysis in respective tumors 
              No LOH 
 
   9 variants in 7 genes 
 
       Loss of wild-type allele one tumor 
 
 
 
 
 
 
 
 
     
                5 variants in 4 genes 
11 candidate CRC predisposing genes  
72,833 missense variants  
excluded 
1,564 truncating variants  
excluded 
1,502 truncating variants 
excluded (present in one case 
only) 
 
542 truncating variants  
excluded 
 
23 false-positive variants  
excluded 
 
9 variants excluded 
 
  
50 
DISCUSSION 
 
1 TTK mutations in microsatellite-unstable colorectal cancer 
 
MSI tumorigenesis is driven by a defective mismatch repair system and results in 
accumulation of frameshift mutations at microsatellite repeats (Aaltonen et al., 1998; 
Salovaara et al., 2000). Many genes have been suggested as MSI targets, usually 
based on high coding repeat frequency, which is thought to be one of the most 
important criteria for identifying true MSI driver genes (Boland et al., 1998). 
Background mutation frequencies are, however, extremely high in this tumor type 
and should always be taken into account when analyzing MSI target genes. We have 
previously generated reference datasets on frameshift mutations occurring in non-
coding repeats to gain better insight into background mutation rates (Sammalkorpi 
et al., 2007; Alhopuro et al., 2012). Coding frameshift mutations at repeats typically 
lead to down-regulation of the target genes due to nonsense-mediated mRNA decay 
(Conti & Izaurralde, 2005). However, frameshift mutations located at the 3’ end of 
the coding regions are often missed by the NMD machinery (Nagy & Maquat, 1998; 
MacArthur et al., 2012). Examples of MSI target genes with such frameshift 
mutations are BAX and TCF7L2 (El-Bchiri et al., 2005). In this study, we sought to 
identify novel MSI target genes with putative oncogenic functions. We systematically 
characterized genes with NMD-decay escaping frameshift mutations that were 
overexpressed in MSI CRCs. 
 
We identified frequent (59%, 105/179) decay-escaping mutations in the mitotic 
checkpoint kinase TTK (also known as MPS1). Repeat mutations in the last exon of 
TTK have been previously reported in 27-52% of MSI tumors. However, these 
studies have included a fairly limited set of tumors (Mori et al., 2002; Ahn et al., 
2009; Kim et al., 2013). In our data, we also found enrichment of exon 5 mutations in 
exon 22 wild-type tumors. Based on our mutational data, TTK mutations appear to 
be selected for during tumor evolution, since the mutation frequency is significantly 
higher under mismatch repair deficiency than observed in identical control repeats. 
In addition, we were able to show the presence of the 34 residues elongated mutant 
protein in heterozygous cell lines, confirming that the mutant mRNA actually does 
escape NMD. Moreover, the mutant form of the protein was shown to locate 
normally to prometaphase kinetochores, which was somewhat expected since 
kinetochore localization has been shown to be mediated by residues in the N-
terminus of TTK (Liu et al., 2003).  
 
The TTK kinase plays important roles in mitotic regulation and spindle-assembly 
checkpoint (SAC) signaling. The SAC checkpoint ensures that chromosome 
segregation occurs correctly. TTK locates to kinetochores where it together with 
other checkpoint components, such as BUB1B and MAD2, delays anaphase onset 
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until all sister chromatids are properly attached to microtubules of the mitotic 
spindle. Major SAC defects have shown to lead to mitotic catastrophe and ultimately 
to apoptosis, whereas minor defects may result in aneuploidy (Kops et al., 2005). 
Several SAC components have shown to be mutated in CIN CRCs, such as BUB1 and 
BUB1B. TTK is also involved in other processes such as centrosome duplication and 
cytokinesis (Fisk et al., 2003).  
 
Since the main function of TTK is to regulate SAC, we wanted to investigate if the 
identified TTK mutations in MSI CRC alter the checkpoint. Mutant MSI CRC cell 
lines were challenged with paclitaxel to test their checkpoint arrest. Paclitaxel is a 
microtubule-stabilizing drug that induces SAC by affecting microtubule dynamics 
and tension (Swanton et al., 2007). Our results showed no evidence for SAC 
impairment in TTK mutant cells. Previous studies have shown the C-terminus of 
TTK to be important for SAC arrest, however, the c.2560delA mutation that 
elongates the C-terminus did not cause SAC override in the cells (Sun et al., 2010).  
TTK is also known to have other cancer-related functions, in addition to SAC 
regulation, that could potentially be affected by the identified mutations. For 
instance, substrate recruitment has been shown to be mediated by the C-terminal 
region of TTK and might be altered by the protein-elongating mutations (Sun et al., 
2010). Previous studies have shown TTK to phosphorylate proteins such as BLM and 
Smad2 and Smad3 (Leng et al., 2006; Zhu et al., 2007). Future studies will also be 
required to determine if the mutations affect the kinase activity of the TTK protein. 
In addition, the oncogenic BRAF (V600E) mutant has been shown to phosphorylate 
TTK, thereby preventing its degradation in melanoma (Liu et al., 2013). Mutated 
BRAF is common in sporadic MSI CRC, but we found no correlation between BRAF 
(V600E) and TTK mutations. Although no functional evidence of oncogenic 
mechanisms for mutant TTK was observed, the high mutation frequency combined 
with the mutation pattern argues for biological significance. Future studies will be 
needed to uncover the effects of the identified TTK mutations in CRC-related 
functions outside SAC.  
2 Oncogenic mutations in microsatellite-unstable colorectal cancer 
 
Today, only few oncogenes have been implicated in MSI tumorigenesis. Well-known 
examples are BRAF, CTNNB1, PIK3CA and KRAS (Rajagopalan et al., 2002; Shitoh et 
al., 2001). Oncogenes usually show highly characteristic and non-random mutation 
patterns, with missense mutations at recurrent positions. BRAF is mutated in 
approximately one-third of MSI tumors and almost always at the codon V600E 
(Rajagopalan et al., 2002). Vogelstein et al. (2013) recently stated that one of the best 
way to identify driver genes mutated in cancer is through analyzing their mutation 
pattern rather than their mutation frequency. In general, MSI tumors are difficult to 
study since they harbor an extremely high number of passenger mutations. We 
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hypothesized that by searching for very specific mutation patterns we can identify 
true driver oncogenes that increase the selective growth advantage of MSI tumor 
cells.  
 
To identify novel MSI CRC oncogenes, we sequenced the exomes of 25 MSI tumors 
and respective healthy tissue. We identified 15 novel candidate oncogenes 
recurrently mutated at the same amino acid positions. ZBTB2, RANBP2 and PSRC1 
were our top hits, since they showed additional hot spot mutations in the validation 
set. The overall frequencies of hot spot mutations were 3.8% (4/106 MSI CRCs), 3.7% 
(4/109) and 4.6% (5/109) for ZBTB2, RANBP2 and PSRC1, respectively. The mutation 
frequencies observed are not that modest, given our strict criterion for hot spots; 
missense mutations had to locate at the same or adjacent codons. For comparison, 
well-known oncogenes such as KRAS and CTNNB1 had hot spot mutation 
frequencies of 8% in the exome data.  
 
Hot spot mutations in our top three genes have not been reported in previous 
systematic sequencing efforts on CRCs. However, none of the studies have had a 
particular focus on MSI CRCs (Seshagiri et al., 2012; Cancer Genome Atlas Network, 
2012). Of note, two other missense mutations, which were also found in our data, 
were reported in RANBP2 and ZBTB2. These mutations located close to our hot spot 
site. In our study, the hot spot mutations in the three top genes were exclusively 
found in MSI CRCs; however, to confirm this finding a larger sample set needs to be 
screened. Interestingly, also in the TCGA data a mutation at our hot spot site in 
ZBTB2 was found in a gastric tumor (MSI status not available, 
http://www.cbioportal.org/public-portal/). The hot spot mutations should be 
screened for in a large set of cancers with MSI, such as endometrial and gastric 
cancers.  
 
2.1 Function of ZBTB2, RANBP2 and PSRC1 in health and disease 
 
The transcription factor ZBTB2 has recently been reported as a central regulator of 
the TP53 pathway, through repressing transcription of ARF, TP53 and P21 and 
activating transcription of HDM2. HDM2 is suggested to induce rapid degradation 
of TP53, which further blocks the protective effect of TP53 in cellular response to 
DNA damage. In our study, the CRC-associated mutant form of ZBTB2 showed an 
increase in long-term cell proliferation. The previous finding that knock-down of 
ZBTB2 decreased cell proliferation (Jeon et al., 2009) further supports an oncogenic 
role for ZBTB2. Based on protein function, ZBTB2 serves as an excellent target for 
activating oncogenic mutations.  
 
RANBP2 (also known as NUP358) is a large nucleoporin, a component of the nuclear 
pore complex, consisting of several domains that each interact directly and 
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selectively with different proteins, the RAS-related GTPase RAN being one of them. 
The interacting proteins all show distinct cellular or molecular functions, 
highlighting the pleiotropic role of RANBP2 (Vetter et al., 1999). Previous studies 
have reported RANBP2 to act as a tumor suppressor by altering chromosomal 
instability by regulating topoisomerase II by sumoylation (Navarro & Bachant, 
2008). RANBP2 is over-expressed in several types of cancers, including CIN CRC cell 
lines, multiple myeloma and mouse prostate cell lines (Dunican et al., 2002; Felix et 
al., 2009; Renner et al., 2007). Interestingly, another study has suggested RANBP2 to 
be involved in CRC tumorigenesis by regulating WNT signaling. Over-expression of 
the protein increased nuclear import of TCF-4 and -catenin, which enhanced 
transcriptional activity and resulted in increased growth of CRC cell lines (Shitashige 
et al., 2008). It is hence possible that the mutated RANBP2, identified here, acts as an 
oncogene by enhancing the transcriptional activity of β-catenin and TCF4, thus 
inducing activation of the WNT signaling pathway.  
 
PSRC1 is a microtubule-binding and bundling protein, the expression of which has 
shown to be elevated in several cancers, supporting an oncogenic role in 
tumorigenesis (Hsieh et al., 2002; Sun et al., 2008). PSRC1 has been linked to 
inhibition of TP53-mediated apoptosis, via inhibition of ASPP2, a regulator of 
apoptosis and cell growth.  The ASPP2-interaction domain of PSRC1 has been 
mapped to amino acids 118-141, covering the hot spot site identified in our study 
(Sun et al., 2008). However, mass spectrometry data did not reveal an altered 
binding to ASPP2 in the mutant cells. Interestingly, PSRC1 has also been shown to 
promote cell growth by enhancing -catenin mediated transcriptional activation of 
the WNT signaling pathway (Hsieh et al., 2007).  However, we observed no evidence 
that the hot spot mutations would cause increased cell proliferation in long-term cell 
cultures.  
 
Much experimental work will be needed to elucidate the detailed functional 
consequences of the identified mutations. Nevertheless, the mutation pattern, 
missense mutations at recurrent locations, combined with the functional roles of 
these three genes provides strong evidence for oncogenic effects in tumorigenesis. 
Driver oncogenes with activating mutations, located at the same amino acid 
positions, are attractive targets for small-molecule inhibitor drugs. For example 
melanoma patients harboring BRAF V600E mutations are already successfully 
treated with specific kinase inhibitors, which result in dramatic tumor remission 
(Chapman et al., 2011). However, as with all cancer therapies, there are some 
immediate limitations that need to be addressed. One challenge is that pathway 
functions are different in different tissues and affected by the accompanied genetic 
alterations. The same drugs that were used to treat melanoma patients have no 
therapeutic effect in CRC patients with BRAF V600E mutations (Mao et al., 2013). 
Also, only a few tumors harbor more than one mutated oncogene, which is a 
challenge for combination strategies in targeted therapies. Nevertheless, there is an 
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urgent need to better understand cancer pathways and driver genes behind cancer 
development. Ultimately, this knowledge will guide the development of more 
effective approaches in cancer treatment.  
 
In the near future, it is estimated that tens of thousands of cancer genomes will be 
sequenced. Large-scale studies will most likely be done by utilizing whole-genome 
sequencing, combined with data on the transcriptome and epigenomes from the 
same cases. Ultimately, these studies will have a great impact on our understanding 
of cancer biology and unravel attractive new strategies for therapies and prevention.  
 
3 Susceptibility genes for common familial colorectal cancer 
 
It is well known that family history is one of the strongest risk factors for the 
development of CRC. Many CRCs develop in genetically susceptible individuals, 
most of whom are not carriers of high-penetrance gene mutations, such as APC or 
mismatch repair mutations (Lichtenstein et al., 2000; Aaltonen et al., 2007; Lubbe et 
al., 2009). Previous studies have reported familial CRC to be fairly common, with 
approximately one tenth of CRC patients having a family history of the disease, if 
excluding high-penetrance mutation carriers (Aaltonen et al., 2007). First-degree 
relatives of CRC patients show a two-fold increase in risk compared to the general 
population (Johns & Houlston, 2001). Despite extensive efforts, the molecular 
background of familial risk remains unexplained. An important part might be 
explained by unknown rare variants of moderate-penetrance.  
3.1 The role of fifteen candidate cancer genes  
 
Sjöblom et al. in 2006 and Wood et al. in 2007 performed the first systematic 
sequencing efforts on nearly all protein-coding genes in breast and colorectal cancer. 
The study by Wood et al. (2007) included a discovery set of 11 breast and 11 
colorectal cancers.  By utilizing a statistical tool that took into account background 
mutation frequencies, 140 somatically mutated candidate cancer (CAN) genes were 
reported, for both cancer types. The CAN genes were ranked based on the likelihood 
of observed gene mutation prevalence exceeding the expected background mutation 
prevalence (Wood et al., 2007). We know from previous studies that somatically 
mutated genes are often involved in hereditary predisposition (Futreal et al., 2004) 
and the novel CAN genes thus serve as obvious candidates for CRC predisposition. 
We analyzed the mutational profile of 15 top-ranked CAN genes (Wood et al., 2007) 
in 45 familial CRC cases for both somatic mutations and germline variants.  
 
Our data on somatic mutations in CAN genes were in good agreement with 
previous studies (Wood et al., 2007; Sjöblom et al., 2006).  As expected, the top-
ranked CAN genes PIK3CA and FBXW7 were the most frequently mutated genes in 
our sample set. PIK3CA encodes for the protein p110, which is the catalytic subunit 
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of the class I PI3-kinase. The gene is a known oncogene with mutations that lead to 
constitutive activation of the PI3K pathway in several common cancers. It has been 
reported that the mutations are clustered and locate mostly in the helical and kinase 
domains of the protein, which was further supported by our findings (Samuels & 
Velculescu, 2004; Ikenoue et al., 2005). FBXW7 is one of the four subunits of the 
ubiquitin ligase complex, which functions in phosphorylation-dependent 
ubiquitination of proteins, such as MYC and cyclin E (Koepp et al., 2001; Yada et al., 
2004). FBXW7 functions as a tumor suppressor, and recent studies have also 
suggested a dominant-negative role of the mutations in cancer development 
(Welcker & Clurman, 2008). 
 
In this effort, we did not identify a clear CRC predisposing gene. Nevertheless, three 
novel non-synonymous germline variants were found in CSMD3, EPHB3 and 
C10orf137, and none of them were present in the 890 population-matched healthy 
controls. Additional studies with larger sample sets will be required to clarify the 
role of these variants in CRC predisposition.  
  
3.2 Identification of susceptibility genes by exome sequencing  
 
Improvements in sequencing technologies have provided novel tools to study cancer 
predisposition in an unbiased manner. In this effort, we sought to identify novel 
susceptibility genes for common familial CRC. CRC families with few affected 
individuals are an attractive patient group to search for novel susceptibility genes, 
but tools for such work have been poor. Here, we performed exome sequencing on 
96 independent familial CRC cases derived from a constitutive collection of 
unselected patients (Aaltonen et al., 1998; Salovaara et al., 2000). All cases were from 
Finland, with a population known for its relatively uniform genetic background. In 
principle, this facilitated gene identification since individuals from isolated 
populations are more likely to share ancestral predisposing mutations, originating 
from a few common founders (Peltonen et al., 2000; Jakkula et al., 2008). In this 
study, we identified 11 genes with rare truncating variants in two or three familial 
CRC cases. They were all absent or rare (MAF  0.001) in the general Finnish 
population. None of the novel candidate susceptibility genes had been previously 
implicated in cancer predisposition. Proposed gene functions and suggested 
pathways in which the encoded proteins are involved are presented in Table 8.  
 
Our effort focused solely on a subset of variants: rare variants with MAF  0.001 in 
the general population. The study was, thus, conducted under the “rare variant 
hypothesis” that proposes that a significant portion of the missing heritability is due 
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to a series of rare variants of moderate-penetrance. However, expressivity may be 
altered by other loci or environmental factors (Fletcher & Houlston, 2010; Bodmer & 
Bonilla, 2008). Evolutionary theory strongly supports this hypothesis by arguing that 
disease promoting variants are selected against and must therefore be rare in the 
population. The hypothesis is further supported by recent empirical population 
genetic data, such as the data from the 1000 Genomes project, which reported rare 
variants to be enriched for deleterious mutations (Gibson, 2011; 1000 Genomes 
Project Consortium et al., 2012). Rare variants are usually population specific and for 
this reason it was important to filter the identified variants against a large number of 
Table 8. Eleven candidate susceptibility genes for common familial CRC*
UACA
uveal autoantigen with 
coiled-coil domains and 
ankyrin repeats
protein binding apoptosis
SFXN4 sideroflexin 4 transporter transmembrane transport
TWSG1
twisted gastrulation BMP 
signaling modulator 1
protein binding 
cell differentation, 
apoptosis 
TGF-β signaling 
PSPH phosphoserine phosphatase phosphatase amino acid biosynthesis serine biosynthesis
NUDT7
nudix (nucleoside 
diphosphate linked moiety 
X)-type motif 7
acetyl-CoA hydrolase
cell differentation, acetyl-
CoA catabolic process
ZNF490 zinc finger protein 490 DNA binding regulation of transcription
PRSS37 protease, serine, 37 protease proteolysis
CCDC18
coiled-coil domain 
containing 18
not known not known
PRADC1
protease-associated 
domain containing 1
not known not known
MRPL3
mitochondrial ribosomal 
protein L3
RNA binding, 
structural constituent 
of ribosome 
translation
AKR1C4
aldo-keto reductase family 
1, member C4
reductase metabolic processes 
androgen and 
estrogen biosynthesis 
Canonical pathway
 * Data on protein functions, biological processes and canonical pathways obtained with Ingenuity Pathways Analyses software 
(www.ingen.com). Only selected protein functions and processes are listed here.  
Gene Gene Description Biological process Protein function 
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population matched healthy controls to further exclude neutral polymorphisms 
(1000 Genomes Project Consortium et al., 2012). 
   
In this study, focus was placed on variants predicted to truncate the protein product, 
so called LoF variants, which are attractive candidates for disease predisposition. 
Previous studies have shown true LoF variants, to be mostly of low frequencies in 
the population. They tend to be mildly or severely deleterious, and have therefore 
been stopped by natural selection from increasing in frequency (MacArthur et al., 
2012; 1000 Genomes Project Consortium et al., 2012). However, recent systematic 
sequencing studies have revealed a surprisingly high number of LoFs in healthy 
individuals, most of which have little or no effect on health. This further highlights 
the challenge to identify true predisposing LoFs from the background of non-
pathogenic polymorphisms. In addition, analysis on gene expression has revealed an 
unanticipated high amount of LoFs to be neutral, with no effect on gene function 
(MacArthur et al., 2012). Further studies are needed to clarify if the LoFs identified 
here are actually genuine LoFs that cause reduction in gene expression.  
Also, the question remains whether the identified candidate genes act as classical 
tumor suppressors. Seven LOH events were observed, involving four of the 
candidate genes. Interestingly, in all seven occasions the wild-type allele was lost 
(P=0.0078), which provides us with additional evidence that true predisposing genes 
are among the eleven genes. In at least a subset of the identified genes, complete 
inactivation seems to be preferentially selected for in tumor evaluation. However, it 
is plausible that some of the candidate genes show alternative mechanisms, such as 
haploinsufficiency or dominant-negative effects. In summary, we have identified an 
interesting set of candidate predisposing genes that may explain a subset of common 
familial CRC. However, additional genetic validation in larger sample sets, 
representing different populations, is required to gain robust evidence for 
pathogenicity. Also, assessing the functional effects of the identified LoFs in tumor 
development and progression would be a crucial next step.  
Exome sequencing is an attractive approach to study susceptibility to cancer, in 
which coding germline variants, at the entire allelic spectrum, can comprehensively 
be investigated. However, studies on rare predisposing variants are at the moment 
largely underpowered. It has been suggested that as many as 10.000 exomes are 
needed to achieve sufficient statistical power to robustly detect associations of rare 
variants with complex traits (Kiezun et al., 2012). Also, associations need to be 
replicated in independent sample sets from different populations. The cost of 
sequencing is falling at a dramatic pace. Exome sequencing, as well as WGS, will in 
the near future be affordable to many research groups. Pooling sequencing data, 
through established consortia, will enable the generation of well-powered 
experiments that will lead to novel discoveries.  
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Noncoding genetics variants, located at regulatory regions, several forms of 
structural variations and polygenic inheritance, have been largely unexplored as a 
basis for CRC susceptibility. Future studies, utilizing WGS, will likely uncover novel 
variants of this class.  
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CONCLUSIONS AND FUTURE PROSPECTS 
 
This study was conducted to provide novel insight into the molecular genetic 
background of CRC. Studies I and II focused on somatic mutations in MSI CRC and 
studies III and IV on germline variants underlying familial CRC predisposition.  
 
I-II 
 
MSI is characteristic for Lynch syndrome and observed in a subset of sporadic CRC 
cases. Until today, only few unbiased large-scale sequencing efforts on MSI CRC 
have been conducted. In addition to many target genes with inactivating mutations, 
only a handful of oncogenes have been implicated in this tumor type. The aim of our 
efforts was to identify novel oncogenes in MSI CRC. In study I, we systematically 
characterized NMD-escaping target genes, overexpressed in MSI tumors. We 
identified frequent frameshift mutations in the mitotic checkpoint kinase TTK that 
resulted in an elongated protein. When compared to background frequencies, TTK 
was found to have significantly higher mutation frequencies than expected without 
clonal selection. By in vitro functional assays, no evidence of oncogenic mechanism 
was observed; however, the high mutation frequency of TTK argues for selection in 
tumorigenesis. In study II, exome sequencing of 25 MSI CRC tumor-normal pairs 
revealed 15 novel candidate oncogenes with hot spot mutations. ZBTB2, RANBP2 
and PSRC1 showed hot spot mutations also in the validation set. Corroborating 
previous data, our results from functional studies on these three genes suggest a role 
in cancer development and progression. Additional efforts are needed to fully 
understand the nature and functional significance of the identified somatic 
mutations in CRC tumorigenesis.  
 
The findings of studies I and II further underline the notion that CRC genomes are 
heterogeneous, characterized by few frequently mutated genes, called mountains 
(e.g. BRAF and PIK3CA), and numerous less frequently mutated genes, called hills 
(e.g. NRAS and here-identified PSRC1, RANBP2 and ZBTB2) (Wood et al., 2007; 
Sjöblom et al., 2006). Creating a comprehensive catalogue of all CRC genes mutated 
at intermediate frequencies, including those identified here, is crucial in order to 
recognize dysregulated pathways and optimal targets for therapeutic intervention. 
In addition, such a catalogue would lead us one step closer to personalized 
medicine, where the choice of combination therapy for each individual patient 
would be based on the cellular pathways dysregulated in their tumor.  
 
Oncogenes with activating hotspot mutations, such as ZBTB2, serve as attractive 
targets for therapeutic interventions. Cancer genome sequencing efforts have already 
had an impact on the clinical care of cancer patients. For example, the identification 
of activating mutations in genes encoding protein kinases has led to the 
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development of small-molecular inhibitors targeting those kinases. Such approaches 
include EGFR kinase inhibitors to treat cancers with EGFR mutations, such as 
gefitinib for non-small-cell lung cancer (Sharma et al., 2007), and specific inhibitors 
of mutant BRAF to treat cancers with BRAF mutations, such as vemurafenib for 
metastatic melanoma (Chapman et al., 2011). In addition, identification of novel 
cancer genes, such as TTK with protein-elongating mutations, may have implications 
for diagnostics and for cancer immunotherapies by providing novel tumor-specific 
antigens. Circulating autoantibodies generated by the immune cells against tumor-
specific antigens can serve as detection patterns of malignancy for earlier cancer 
diagnosis and predicting outcomes (Casino et al., 2006). Moreover, such antigens 
could be used in already existing platforms for immunotherapy of cancers, such as 
vaccines containing the immunogenic mutant peptides, antibodies developed 
against the tumor-specific antigens, or T cells with reactivity directed against the 
mutant proteins (Kirkwood et al., 2011). 
 
In the near future, as more tumors are being sequenced, it will be fairly 
straightforward to identify all genes mutated at elevated rates in CRC. However, 
characterization of their functional role in tumorigenesis will be a crucial, yet 
challenging task. Furthermore, studies to characterize and interpret alterations in 
noncoding DNA, DNA methylation, mRNA expression and protein expression in 
CRC are only in their early stages.  
 
III-IV 
 
Hereditary factors are presumed to play a major role in CRC risk; however, still 
today the etiology of familial CRC is largely unknown. This is particularly the case 
for common CRC families with few affected individuals. In study III, fifteen top-
ranked somatically mutated CRC genes, previously published by Wood et al. (2007), 
were screened for germline mutations in familial CRC cases. None of the genes were 
shown to clearly predispose to familial CRC; however, three novel missense variants 
were identified that were absent in population matched controls. In study IV, we 
exome sequenced 96 independent familial CRC cases, with typically only one 
affected first-degree relative. We identified eleven novel candidate predisposing 
genes with rare protein-truncating variants in familial CRC cases. Seven LOH events 
were observed in the respective tumors and in all occasions the wild-type allele was 
lost, which provides us with additional evidence that true culprits are among these 
genes. 
 
The architecture of inherited genetic susceptibility to CRC is complex: characterized 
by multiple predisposition alleles with different levels of risk and prevalence in the 
population. Our results expand on the existing repertoire of genes that might 
predispose to CRC. Further investigations, including genetic validation in large 
sample sets representing different populations, are required to provide robust 
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evidence for disease causality. Additional work is also needed to characterize the 
detailed functional and clinical relevance of the identified candidate CRC 
predisposing genes.  
 
In the next few years, exome sequencing-efforts with large sample sets will most 
likely identify many more variants associated with CRC. A future challenge to be 
faced might not lie in the identification of the association signals alone, but rather in 
characterizing the molecular mechanisms in which they influence cancer risk. Such 
insights will provide greater understanding of cancer biology in general and reveal 
potential targets for diagnostic and therapeutic strategies. Also, such information 
would be of immediate clinical relevance in regard to cancer risk assessment. The 
identification of individuals at increased risk allows for targeted cancer prevention 
strategies and can also influence cancer treatment options.  
 
There is an urgent need for new technologies that would transform functional 
genomics in cancer research. Efficient large-scale functional studies will be required 
to ultimately characterize the genes and pathways important in cancer development. 
The functional consequences of putative LoF variants, including those identified in 
this study, can currently be investigated with, for instance, RNA interference and 
novel genome editing technologies, such as the promising RNA-guided CRISPR-
Cas9 system (Wang et al., 2014). Results from such approaches could further guide 
the construction of animal model experiments that are crucial in understanding 
processes of human pathophysiology.  
 
Exome sequencing has its limitations in studying the genetic architecture, since 
noncoding variants, for instance at regulatory regions, are missed, while being likely 
important for cancer predisposition. Moreover, currently little is understood of the 
polygenic basis and gene-environment interactions behind CRC predisposing. Still 
today, much of the inherited predisposition to CRC remains unaccounted for, thus 
highlighting the need for further efforts. Ultimately, improved knowledge of CRC 
predisposition will guide the development of more effective strategies for reducing 
CRC morbidity and mortality.   
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